<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke - Wardlaw, JM - 2013 | Cochrane Library</title> <meta content="Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke - Wardlaw, JM - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000514.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke - Wardlaw, JM - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000514.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000514.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke" name="citation_title"/> <meta content="Joanna M Wardlaw" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="joanna.wardlaw@ed.ac.uk" name="citation_author_email"/> <meta content="Panos Koumellis" name="citation_author"/> <meta content="Hurstwood Park Neurosciences Centre" name="citation_author_institution"/> <meta content="Ming Liu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD000514.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/05/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000514.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000514.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000514.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Thrombolytic Therapy [adverse effects]; Acute Disease; Brain Ischemia [*drug therapy]; Cerebral Hemorrhage [*chemically induced, epidemiology]; Fibrinolytic Agents [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Stroke [*drug therapy]; Tenecteplase; Tissue Plasminogen Activator [administration &amp; dosage, adverse effects]; Urokinase‐Type Plasminogen Activator [administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000514.pub3&amp;doi=10.1002/14651858.CD000514.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000514\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000514\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","ko","fr","ta"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000514.pub3",title:"Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke",firstPublishedDate:"May 31, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000514.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000514.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000514.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000514.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000514.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000514.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000514.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000514.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000514.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000514.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12080 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000514.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#CD000514-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#CD000514-sec1-0006"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#CD000514-sec1-0001"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#CD000514-sec1-0002"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#CD000514-sec1-0003"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#CD000514-sec1-0004"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#CD000514-sec1-0005"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/appendices#CD000514-sec1-0011"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/table_n/CD000514StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/table_n/CD000514StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information#CD000514-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Joanna M Wardlaw</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information#CD000514-cr-0003">Panos Koumellis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information#CD000514-cr-0004">Ming Liu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information/en#CD000514-sec1-0016">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 May 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000514.pub3">https://doi.org/10.1002/14651858.CD000514.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000514-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000514-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000514-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000514-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000514-abs-0003">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000514-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000514-abs-0001" lang="en"> <section id="CD000514-abs1-0001"> <h3 class="title" id="CD000514-abs1-0001">Background</h3> <p>Stroke is a leading cause of death and disability world wide. Thrombolysis with recombinant tissue plasminogen activator (rt‐PA) is licensed for treatment of acute ischaemic stroke in the early hours after symptom onset. It has been shown in randomised controlled trials (RCTs) and the 2009 Cochrane review of thrombolysis for acute ischaemic stroke to reduce dependency but at the increased risk of intracranial haemorrhage. Methods to reduce the risk of haemorrhage while retaining or enhancing the benefit could increase the use of thrombolytic treatment. While most available information comes from RCTs of intravenous rt‐PA at 0.9 mg/kg, it is possible that other doses, drugs and other routes of administration might increase benefit and reduce the hazard. </p> </section> <section id="CD000514-abs1-0002"> <h3 class="title" id="CD000514-abs1-0002">Objectives</h3> <p>To assess the risks and benefits of different thrombolytic agents, doses and routes of administration for the treatment of acute ischaemic stroke. </p> </section> <section id="CD000514-abs1-0003"> <h3 class="title" id="CD000514-abs1-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (May 2012), MEDLINE (1966 to May 2012) and EMBASE (1980 to May 2012). We handsearched journals and conference proceedings, searched ongoing trials registers and contacted pharmaceutical companies and researchers. </p> </section> <section id="CD000514-abs1-0004"> <h3 class="title" id="CD000514-abs1-0004">Selection criteria</h3> <p>Unconfounded randomised and quasi‐randomised trials of different doses of a thrombolytic agent, or different agents, or the same agent given by different routes, in people with confirmed acute ischaemic stroke. </p> </section> <section id="CD000514-abs1-0005"> <h3 class="title" id="CD000514-abs1-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial eligibility and quality, and extracted the data using a structured proforma. We cross‐checked and resolved discrepancies by discussion to reach consensus. We obtained translations and additional information from study authors where required. </p> </section> <section id="CD000514-abs1-0006"> <h3 class="title" id="CD000514-abs1-0006">Main results</h3> <p>We included 20 trials involving 2527 patients. Concealment of allocation was poorly described. Different doses (of tissue plasminogen activator, urokinase, desmoteplase or tenecteplase) were compared in 13 trials (N = 1433 patients). Different agents (tissue plasminogen activator versus urokinase, tissue‐cultured urokinase versus conventional urokinase, tenecteplase versus tissue plasminogen activator) were compared in five trials (N = 875 patients). Five trials (N = 485) compared different routes of administration. As some trials compared different agents and different doses, some patients contributed to two analyses. There was an approximately three‐fold increase in fatal intracranial haemorrhages in patients allocated to higher than to lower doses of the same thrombolytic drug (odds ratio (OR) 2.71, 95% confidence interval (CI) 1.22 to 6.04). There was no difference in the number of patients who were dead or dependent at the end of follow‐up between those allocated higher or lower doses of thrombolytic drug (OR 0.86, 95% CI 0.62 to 1.19). Higher versus lower doses of desmoteplase were associated with more deaths at the end of follow‐up (OR 3.21, 95% CI 1.23 to 8.39). There was no evidence of any benefit for intra‐arterial over intravenous treatment. </p> </section> <section id="CD000514-abs1-0007"> <h3 class="title" id="CD000514-abs1-0007">Authors' conclusions</h3> <p>These limited data suggest that higher doses of thrombolytic agents may lead to higher rates of bleeding. However, the evidence is inadequate to conclude whether lower doses of thrombolytic agents are more effective than higher doses, or whether one agent is better than another, or which route of administration is the best, for acute ischaemic stroke. At present, intravenous rt‐PA at 0.9mg/kg as licensed in many countries appears to represent best practice and other drugs, doses or routes of administration should only be used in randomised controlled trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000514-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000514-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000514-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000514-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000514-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000514-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ta#CD000514-abs-0010">தமிழ்</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000514-abs-0006" lang="en"> <h3>Clot‐dissolving drugs (different doses, routes of administration and agents) for breaking down a blood clot blocking a blood vessel in the brain </h3> <p>Many strokes are due to a sudden blockage of an artery in the brain. Treatments to dissolve the clot (also called thrombolytic treatment) can improve the chance of making a good recovery from a stroke. This review aimed to find out if there were important differences between different clot‐dissolving drugs. It also aimed to find out if there were differences in effect when giving the same drug in different doses or by different routes (into an artery or a vein). The review, which included 20 studies involving 2527 participants, showed that there was some evidence that lower doses of thrombolytic agents led to serious bleeding in the brain less often. However, it was not clear if the benefit from lower doses was as big as with higher doses. There was no evidence to show that one thrombolytic agent was clearly better than another, or that intra‐arterial treatment was better than intravenous treatment. Therefore, more larger randomised controlled trials are required to answer questions about which drug, or dose or route of administration is best for thrombolysis. At present, rt‐PA as currently licensed in many countries, should be regarded as best practice. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000514-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000514-sec1-0006"></div> <h3 class="title" id="CD000514-sec1-0007">Implications for practice</h3> <section id="CD000514-sec1-0007"> <p>The data provide limited evidence that higher doses of thrombolytic drugs lead to higher rates of fatal intracranial haemorrhage. Apart from that, the data are insufficient to answer questions about which drug or dose might be best for thrombolysis. That is not to say that one drug might be better (or worse) than others, but simply that the randomised evidence does not exist. Data on route of administration are more substantial and do not support routine use of intra‐arterial therapy over intravenous therapy. At present intravenous rtPA as licensed should be regarded as best practice. Please refer to the Cochrane review of 'Thrombolysis for acute ischaemic stroke' (<a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>) for conclusions on the broader question of the use of any thrombolytic agent, and of rt‐PA specifically (<a href="./references#CD000514-bbs2-0112" title="WardlawJM , MurrayV , BergeE , delZoppoG , SandercockP , LindleyRL , et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta‐analysis. Lancet2012;379:2364‐72. ">Wardlaw 2012</a>), in acute ischaemic stroke. </p> </section> <h3 class="title" id="CD000514-sec1-0008">Implications for research</h3> <section id="CD000514-sec1-0008"> <p>More, larger randomised controlled trials are required to answer questions about which drug, or dose is best for thrombolysis, and whether there are any situations in which intra‐arterial therapy with or without a mechanical clot extracting device is better than intravenous rt‐PA. Such trials should collect data on functional outcome assessed using the modified Rankin Scale or Barthel Index at a minimum of three months after the stroke, and should clearly define intracranial haemorrhage in terms of its clinical effects (for example 'asymptomatic', 'symptomatic' or 'fatal'). Patients dying of neurological causes without immediate prior brain imaging should, wherever possible, undergo autopsy examination. </p> <p>There are no randomised comparisons of streptokinase with rt‐PA or urokinase, only of rt‐PA with urokinase or tenecteplase. Larger randomised trials are required to evaluate the newer thrombolytic agents such as desmoteplase and tenecteplase and compare them to the widely used rt‐PA. Future trials also need to address whether interventional management of stroke offers any particular advantage and in which group of patients. Future trials could usefully address these areas to try to find ways of reducing the risk (and improving the chance of benefit) with thrombolysis. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000514-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000514-sec1-0001"></div> <section id="CD000514-sec2-0001"> <h3 class="title" id="CD000514-sec2-0001">Description of the condition</h3> <p>Stroke is a leading cause of death and disability world wide. Most strokes are ischaemic and due to a thrombotic or embolic occlusion of an intracranial artery. Rapid administration of intravenous thrombolytic therapy with the drug recombinant tissue plasminogen activator (rt‐PA, generic name alteplase) is the principal treatment in the early hours after the onset of symptoms and has been shown in randomised controlled trials (RCTs) to improve outcomes (<a href="./references#CD000514-bbs2-0112" title="WardlawJM , MurrayV , BergeE , delZoppoG , SandercockP , LindleyRL , et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta‐analysis. Lancet2012;379:2364‐72. ">Wardlaw 2012</a>; additional information in <a href="./references#CD000514-bbs2-0101" title="HackeW , DonnanG , FieschiC , KasteM , vonKummerR , BroderickJP , et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt‐PA stroke trials. Lancet2004;363:768‐74. ">Hacke 2004</a> and <a href="./references#CD000514-bbs2-0104" title="LeesKR , BluhmkiE , VonKummerR , BrottTG , ToniD , GrottaJC , theECASS , ATLANTIS , NINDS and EPITHET rt‐PA Study Group Investigators. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS and EPITHET trials. Lancet2010;375:1695‐703. ">Lees 2010</a>). Although rt‐PA is the only thrombolytic drug licensed for the treatment of acute ischaemic stroke, other thrombolytic drugs have also shown promise (<a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>; <a href="./references#CD000514-bbs2-0111" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischemic stroke. Stroke2010;41:e445‐6. ">Wardlaw 2010</a>). The earlier the thrombolytic agent is administered the more patients remain alive and independent (<a href="./references#CD000514-bbs2-0104" title="LeesKR , BluhmkiE , VonKummerR , BrottTG , ToniD , GrottaJC , theECASS , ATLANTIS , NINDS and EPITHET rt‐PA Study Group Investigators. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS and EPITHET trials. Lancet2010;375:1695‐703. ">Lees 2010</a>; <a href="./references#CD000514-bbs2-0112" title="WardlawJM , MurrayV , BergeE , delZoppoG , SandercockP , LindleyRL , et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta‐analysis. Lancet2012;379:2364‐72. ">Wardlaw 2012</a>). However, the major risk of the treatment is intracranial haemorrhage, which is the single most frequent cause of death following thrombolysis regardless of which drug is used (<a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>; <a href="./references#CD000514-bbs2-0111" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischemic stroke. Stroke2010;41:e445‐6. ">Wardlaw 2010</a>; <a href="./references#CD000514-bbs2-0112" title="WardlawJM , MurrayV , BergeE , delZoppoG , SandercockP , LindleyRL , et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta‐analysis. Lancet2012;379:2364‐72. ">Wardlaw 2012</a>). Systemic bleeding is a less common but potentially serious complication. </p> </section> <section id="CD000514-sec2-0002"> <h3 class="title" id="CD000514-sec2-0002">Description of the intervention</h3> <p>Most of the randomised controlled trials (RCTs) of thrombolytic drugs to date have tested intravenous rt‐PA but other routes of administration, drugs or doses of drug might reduce hazard or be more beneficial. Intra‐arterial thrombolysis offers some theoretical advantages such as regionally localised therapy, reduced overall dose and hence systemic effects of thrombolytic therapy. However, this comes at the cost of a more invasive technique, delay in treatment initiation and the requirement for a specialised radiological unit. Despite this, in recent years there has been increasing interest in intra‐arterial therapy and also in mechanical devices to extract the intraluminal clot with or without the use of pharmacological thrombolysis (<a href="./references#CD000514-bbs2-0103" title="LeeM , HongKS , SaverJL . Efficacy of intra‐arterial fibrinolysis for acute ischemic stroke: meta‐analysis of randomized controlled trials. Stroke2010;41:932‐7. ">Lee 2010</a>; <a href="./references#CD000514-bbs2-0105" title="LindsbergPJ , MattleHP . Therapy of basilar artery occlusion: a systematic analysis comparing intra‐arterial and intravenous thrombolysis. Stroke2006;37:922‐8. ">Lindsberg 2006</a>; <a href="./references#CD000514-bbs2-0106" title="LisboaRC , JovanovicBD , AlbertsMJ . Analysis of the safety and efficacy of intraarterial thrombolytic therapy in ischaemic stroke. Stroke2002;33:2866‐71. ">Lisboa 2002</a>; <a href="./references#CD000514-bbs2-0107" title="MazighiM , SerfatyJM , LabreucheJ , LaissyJP , MeseguerE , LavalléePC , et al. Comparison of intravenous alteplase with a combined intravenous‐endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet2010;8:802‐9. ">RECANALISE 2009</a>). However, there are as yet no completed randomised trials testing mechanical devices, although some are expected to start soon. </p> <p>Apart from rt‐PA, other thrombolytic drugs have also been tested in stroke. Two RCTs testing streptokinase were terminated early due to a high rate of symptomatic haemorrhage and a third was stopped due to the adverse climate generated by termination of the other two, although the third trial had not demonstrated any excess hazard (<a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>; <a href="./references#CD000514-bbs2-0111" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischemic stroke. Stroke2010;41:e445‐6. ">Wardlaw 2010</a>). Urokinase has been used in the treatment of stroke, although less often recently. Newer thrombolytic agents, such as tenecteplase and desmoteplase, are variants of the native plasminogen activators and are currently being evaluated as alternative fibrinolytic agents. </p> </section> <section id="CD000514-sec2-0003"> <h3 class="title" id="CD000514-sec2-0003">How the intervention might work</h3> <p>Alternative routes of administration, drugs or doses might reduce hazard whilst preserving benefit. Amongst trials mostly comparing intravenous thrombolysis with control (summarised in <a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>; <a href="./references#CD000514-bbs2-0111" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischemic stroke. Stroke2010;41:e445‐6. ">Wardlaw 2010</a>), there was marked heterogeneity in case fatality rates. It was possible to explore reasons for the heterogeneity only in a very limited way but several points emerged. For example, the case fatality at the end of follow‐up in the thrombolysis‐treated patients was lower in the trials that tested lower doses of thrombolytic drug than in the trials that tested doses similar to those used to treat acute myocardial infarction (MI), although the difference was not statistically significant and there was no obvious trend in case fatality between the trials using the lowest and highest doses. There are of course many other reasons for the between‐trial heterogeneity. </p> </section> <section id="CD000514-sec2-0004"> <h3 class="title" id="CD000514-sec2-0004">Why it is important to do this review</h3> <p>The available data on the use of thrombolytic drugs to treat acute ischaemic stroke have posed questions for further research. Do lower doses of thrombolytic drugs reduce the hazard without compromising the benefit? Which thrombolytic drug has the least hazard and most benefit or are they all the same? Which is the best route of administration: intravenous, intra‐arterial or other? </p> <p>Recently, with the development of several newer thrombolytic drugs, there have been more trials testing different doses and comparing different drugs with the licensed drug rt‐PA. We updated this systematic review to identify what information there is concerning choice of thrombolytic drug, dose and route of administration for treating acute ischaemic stroke. We sought to identify which, if any, regimen might have the most benefit and least hazard in acute ischaemic stroke, and highlight where more trials are needed. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000514-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000514-sec1-0002"></div> <p>The aims of this review were as follows.</p> <p> <ol id="CD000514-lst1-0001"> <li> <p>To compare a higher dose with a lower dose of thrombolytic therapy to determine whether there are important differences in: </p> <ol id="CD000514-lst2-0001"> <li> <p>the proportion with poor long‐term outcome (efficacy);</p> </li> <li> <p>the number of early deaths (safety);</p> </li> <li> <p>the number of deaths by the end of the scheduled follow‐up period (safety); and</p> </li> <li> <p>symptomatic (including fatal) intracranial haemorrhage (safety).</p> </li> </ol> </li> <li> <p>To compare one thrombolytic agent with an equivalent dose of another agent to see whether there are important differences in: </p> <ol id="CD000514-lst2-0002"> <li> <p>the proportion with poor long‐term outcome (efficacy);</p> </li> <li> <p>the number of early deaths (safety);</p> </li> <li> <p>the number of deaths by the end of the scheduled follow‐up period (safety); and</p> </li> <li> <p>symptomatic (including fatal) intracranial haemorrhage (safety).</p> </li> </ol> </li> <li> <p>To compare intravenous with intra‐arterial thrombolysis (with the same agent) to see whether there are important differences in: </p> <ol id="CD000514-lst2-0003"> <li> <p>the proportion with poor long‐term outcome (efficacy);</p> </li> <li> <p>the number of early deaths (safety);</p> </li> <li> <p>the number of deaths by the end of the scheduled follow‐up period (safety); and</p> </li> <li> <p>symptomatic (including fatal) intracranial haemorrhage (safety).</p> </li> </ol> </li> </ol> </p> <p>The primary outcome in this review was poor functional outcome at the end of follow‐up. We considered early and total deaths at the end of follow‐up, symptomatic and fatal intracranial haemorrhages and major extracranial haemorrhages to be secondary outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000514-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000514-sec1-0003"></div> <section id="CD000514-sec2-0005"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000514-sec3-0001"> <h4 class="title">Types of studies</h4> <p>All unconfounded truly randomised or quasi‐randomised trials in patients with acute ischaemic stroke within 14 days of stroke onset in which: </p> <p> <ol id="CD000514-lst1-0002"> <li> <p>a lower dose of the thrombolytic agent was compared with a higher dose of the same agent; or </p> </li> <li> <p>one thrombolytic agent was compared with another agent; or</p> </li> <li> <p>two different routes of administration of the same agent were compared.</p> </li> </ol> </p> <p>We included trials that had a placebo group as well as two groups receiving different doses of the same thrombolytic agent, but the placebo patients do not appear in this review. Trials comparing thrombolysis with placebo are presented in the Cochrane review of 'Thrombolysis for acute ischaemic stroke' (<a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>; <a href="./references#CD000514-bbs2-0111" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischemic stroke. Stroke2010;41:e445‐6. ">Wardlaw 2010</a>). </p> </section> <section id="CD000514-sec3-0002"> <h4 class="title">Types of participants</h4> <p>Trials which included patients of any age or sex within 14 days of onset of acute ischaemic stroke (pre‐randomisation computerised tomography (CT) or magnetic resonance imaging (MRI) having excluded cerebral haemorrhage as the cause of symptoms) were eligible. Although it is likely that thrombolysis is most effective if given within the first few hours of stroke, we have included trials treating patients at comparatively late stages in this version of the review because, in general, the trials that treated patients late were testing very low doses ‐ i.e. a different approach to the use of thrombolysis and there was no good logical reason for excluding these trials at this stage. In future, should more data become available, it will be possible to conduct sensitivity analyses of early high‐dose versus later lower‐dose treatment. </p> </section> <section id="CD000514-sec3-0003"> <h4 class="title">Types of interventions</h4> <p>We included trials that tested, in a randomised design, any type of thrombolytic drug ‐ urokinase (UK), pro‐urokinase (PRO‐UK), streptokinase (SK), recombinant and tissue plasminogen activator (rt‐PA and t‐PA respectively), tenecteplase (TNK), desmoteplase, retevase or lumbrokinase (LK) ‐ either in different doses (e.g. lower dose of half to two‐thirds of that of a higher dose) or by different administrative methods (of the same drug) or comparing different drugs to treat acute ischaemic stroke. The drugs could be given intravenously, intra‐arterially or orally (where appropriate). We excluded confounded trials (e.g. lower dose of thrombolytic drugs plus another agent versus higher dose of thrombolytic drug). </p> </section> <section id="CD000514-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <p>We considered five main outcomes.</p> <section id="CD000514-sec4-0001"> <h5 class="title">Primary outcomes</h5> <p>Poor functional outcome at the end of follow‐up (where follow‐up was performed at one month or longer after the stroke). This was defined as death or dependency on others in activities of daily living, at the end of the trial follow‐up period where this was one month or later after the stroke (although we accept that dependency measured earlier than three months may not allow sufficient time for maximum recovery to have occurred). </p> </section> <section id="CD000514-sec4-0002"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD000514-lst1-0003"> <li> <p>Death from any cause and vascular/unknown death (a) within the first two weeks of treatment, and (b) during the whole trial follow‐up period (we included trials with final follow‐up at one month or longer). </p> </li> <li> <p>Intracranial haemorrhage: symptomatic (i.e. associated with a deterioration in the patient's neurological state) and fatal (i.e. leading directly to the death of the patient). Intracranial haemorrhage includes haemorrhagic transformation of the infarct, haemorrhage elsewhere in the brain, and haemorrhage into the spaces surrounding the brain. </p> </li> <li> <p>Major extracranial haemorrhage (i.e. fatal or requiring a transfusion or an operation).</p> </li> <li> <p>Other major extracranial events (e.g. deep vein thrombosis (DVT), ischaemic leg and haematoma at the puncture site following angiography). </p> </li> </ol> </p> </section> </section> </section> <section id="CD000514-sec2-0006"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialized register' section in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html" target="_blank">Cochrane Stroke Group</a> module. We searched for relevant trials in all languages and arranged translation of trial reports published in languages other than English. </p> <section id="CD000514-sec3-0005"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Managing Editor in May 2012. We also searched MEDLINE (1966 to May 2012) (<a href="./appendices#CD000514-sec2-0011">Appendix 1</a>) and EMBASE (1980 to May 2012) (<a href="./appendices#CD000514-sec2-0012">Appendix 2</a>). We included trials known to be completed and published by Febuary 2013. </p> <p>We sought Information from the Stroke Trials Registry (<a href="http://www.strokecenter.org/trials" target="_blank">www.strokecenter.org/trials</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>), EU Clinical Trials Register (<a href="http://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>), Current Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>) and the WHO International Clinical trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). We used Google to search for individual trial names and then searched any online resources of the relevant trials (e.g. trials websites). </p> </section> <section id="CD000514-sec3-0006"> <h4 class="title">Searching other resources</h4> <p>We handsearched the following journals from 1979 to April 1994 for the first review: <i>Japanese Journal of Stroke</i> ; <i>Clinical Evaluation</i> ; <i>Japanese Journal of Pharmacology &amp; Therapeutics</i> ; <i>Rinsho Ketsueki</i> . We obtained translations of the non‐English language publications from people in whose native language the paper was published. For the latest update of the review, and in order to validate the results of the MEDLINE and EMBASE searches, we handsearched three journals (<i>American Journal of Neuroradiology</i> , <i>New England Journal of Medicine</i> and <i>Stroke</i>) from January 2006 to December 2010. </p> <p>In 1997 we contacted all pharmaceutical companies listed in the British National Formulary (BNF) and the Monthly Index of Medical Specialties (MIMS) for more information about trials, both those known to exist from the above efforts, and any trials which were unknown to the review authors. Only one company, Genentech, an American company, did not respond. For the previous update we contacted Gruenenthal for trial details. We did not contact any other companies for this update. </p> <p>We searched the abstracts presented at international conferences for acute stroke (the European Stroke Conferences 1991 to 2012, the biennial International Symposia on Thrombolysis in Acute Ischaemic Stroke 1992 to 2011, the biennial World Stroke Conferences 2000 to 2012, and the American Heart Association International Stroke Conferences 1990 to 2013). We also searched abstracts of other neurological and cerebrovascular symposia as published in journals and through colleagues who attended. </p> <p>We contacted the principal investigators of trials in Europe, the USA, Japan and China when we required additional information. </p> </section> </section> <section id="CD000514-sec2-0007"> <h3 class="title" id="CD000514-sec2-0007">Data collection and analysis</h3> <section id="CD000514-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>For the update of this review two authors (PK, JMW) independently screened titles and abstracts, excluded obviously irrelevant articles and selected trials for inclusion in the review. We resolved any disagreements by discussion. We obtained the full text of the remaining articles and the same two authors independently selected studies meeting the inclusion criteria. We resolved any further disagreements by discussion if necessary. One author (PK) extracted data on the methodological quality and outcome assessments. The other author (JMW) cross‐checked all the extracted data and we resolved differences by discussion if necessary. </p> </section> <section id="CD000514-sec3-0008"> <h4 class="title">Data extraction and management</h4> <p>Review authors extracted data by using a standard proforma (ML and JMW for trials included in the previous version of the review; PK and JMW for trials identified since the last version of this review). The review authors resolved disagreements by discussion or by correspondence with the trial authors. For the most recent update, PK entered data into Review Manager (<a href="./references#CD000514-bbs2-0108" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>) and JMW checked the data. </p> </section> <section id="CD000514-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We collected information about the method of randomisation, allocation concealment, blinding (both of treatment administration and of outcome assessment), whether an intention‐to‐treat analysis was done or could possibly be done and the number of patients who were lost to follow‐up, to assess the methodological quality and risk of bias in the included studies (<a href="./references#CD000514-bbs2-0102" title="HigginsJPT , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook of Systematic Reviews of Interventions. 5.1. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD000514-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <p>For outcome assessment we extracted the number of patients originally allocated to each treatment group irrespective of compliance to allow an intention‐to‐treat analysis (trials that included a placebo group are included in the present review, but the placebo patients are included in the Cochrane review of 'Thrombolysis for acute ischaemic stroke' (<a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>; <a href="./references#CD000514-bbs2-0111" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischemic stroke. Stroke2010;41:e445‐6. ">Wardlaw 2010</a>), and trials of rt‐PA are published in the 2012 systematic review (<a href="./references#CD000514-bbs2-0112" title="WardlawJM , MurrayV , BergeE , delZoppoG , SandercockP , LindleyRL , et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta‐analysis. Lancet2012;379:2364‐72. ">Wardlaw 2012</a>), not in this review). </p> <p>We then collected the number of patients who:</p> <p> <ol id="CD000514-lst1-0004"> <li> <p>died in the early stage (within the first two weeks of the stroke) and by the end of the trial follow‐up; </p> </li> <li> <p>were disabled (dependent on others in activities of daily living) by the end of the trial follow‐up period. We defined dependency as a score of three to five on the modified Rankin Scale (mRS) (or equivalent); </p> </li> <li> <p>developed symptomatic or fatal intracranial haemorrhage (confirmed by CT or MR or post mortem) in the acute stage. We defined symptomatic intracranial haemorrhage as intracranial haemorrhage, confirmed by a CT, MR scan, lumbar puncture or autopsy, accompanied by deterioration in the neurological condition of the patient. Fatal intracranial haemorrhage is death attributed to intracranial haemorrhage confirmed by CT or MR brain imaging or post mortem examination. There is a problem with the estimation of the true number of symptomatic or fatal intracranial haemorrhages because some patients died without a CT or MR scan or post mortem. Patients who died in the acute stage of neurological causes may have had an intracranial haemorrhage, so we collected the number of patients who had symptomatic intracranial haemorrhage or who died in the acute stage to avoid underestimation of major intracerebral haemorrhage; </p> </li> <li> <p>had major extracranial haemorrhage, defined as haemorrhage outside the cranial cavity that resulted in clinical deterioration of the patient, prolonged immobility or stay in hospital, or required transfusion or surgical evacuation; </p> </li> <li> <p>had complications that might be a consequence of the administration route, e.g. groin haematoma or limb ischaemia following angiography. </p> </li> </ol> </p> </section> <section id="CD000514-sec3-0011"> <h4 class="title">Unit of analysis issues</h4> <p>We used mRS scores where available. Where not available we converted other relevant stroke scales to the mRS. Where it was not possible to convert, or where functional outcome was not assessed, we omitted the trial from analysis of functional outcome. The only other outcome where there was potential for variable measures was symptomatic intracranial haemorrhage. Here we used the trial‐specific definition and did not attempt to convert these to some other standard as there is no consensus on how symptomatic intracranial haemorrhage should be standardised, nor did the trials provide information to allow any conversion. </p> </section> <section id="CD000514-sec3-0012"> <h4 class="title">Dealing with missing data</h4> <p>We sought missing data from trial investigators and any other associated contacts. If it was not possible to obtain data omitted from the trial publication, we omitted the trial from that analysis. These are highlighted in the results section. We have used all available data. </p> </section> <section id="CD000514-sec3-0013"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity using the I² statistic. We also reported the Chi² test in the tables and figures (<a href="./references#CD000514-bbs2-0098" title="Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy ‐ I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81‐106. ">APT 1994</a>). </p> </section> <section id="CD000514-sec3-0014"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting biases using funnel plots.</p> </section> <section id="CD000514-sec3-0015"> <h4 class="title">Data synthesis</h4> <p>We calculated the Peto odds ratios for each outcome.</p> </section> <section id="CD000514-sec3-0016"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We also attempted to collect information on baseline characteristics of the patients, such as the severity of the stroke at randomisation, age of the patients, gender, etc. We hoped to be able to perform subgroup analyses based on these characteristics should the data be sufficient. </p> </section> <section id="CD000514-sec3-0017"> <h4 class="title">Sensitivity analysis</h4> <p>The main analyses were based on all trials. However, we also planned a priori sensitivity analyses based on: </p> <p> <ol id="CD000514-lst1-0005"> <li> <p>trials with well‐concealed treatment allocation (i.e. allocation was given by telephoning a central office; by first entering the data into a computer; by the pharmacy; by using identical numbered containers; or by sequentially numbered, sealed, opaque envelopes) versus less well concealed allocation; </p> </li> <li> <p>trials with blinded outcome assessment versus unblinded assessment.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000514-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000514-sec1-0004"></div> <section id="CD000514-sec2-0008"> <h3 class="title">Description of studies</h3> <section id="CD000514-sec3-0018"> <h4 class="title">Results of the search</h4> <p>The searches of the Cochrane Stroke Group Trials Register, MEDLINE and EMBASE yielded 3672 potentially relevant abstracts but the majority were either completely irrelevant or excluded through being non‐randomised comparisons, not testing comparisons relevant to this review, randomised but no relevant outcome reported, or confounded by another drug or intervention. Of these, 71 were relevant enough to be listed in the excluded studies section, five are ongoing, one is awaiting assessment but may prove to be irrelevant and 20 met the inclusion criteria. </p> <p>Five trials (<a href="./references#CD000514-bbs2-0093" title="BASICS. Ongoing study To be confirmed. ">BASICS</a>; <a href="./references#CD000514-bbs2-0094" title="Lundbeck JapanKK . Clinical study of desmoteplase in Japanese patients with acute ischemic stroke (DIAS‐J). ClinicalTrials.gov2010. MoriE . Desmoteplase in Japanese patients with acute ischaemic stroke (DIAS‐J): study objectives of a randomised, double‐blind, placebo‐controlled, dose escalation trial. International Journal of Stroke2010;5 Suppl 2:192. PennerR . Paion's partner Lundbeck initiates Japanese clinical phase II trial with desmoteplase in ischaemic stroke. http://www.paion.de/images/stories/investoren/finanznachrichten/2010/en/pm_dias‐j_enfinal.pdf2010. vonKummerR , AlbersGW , on behalf of the DIAS Steering Committee. Desmoteplase in Acute Ischaemic Stroke: status updated on the DIAS clinical trial programme. Poster presented at the 2011 European Stroke Conference; May 24‐27, 2011; Hamburg, Germany2011. ">DIAS‐J</a>; <a href="./references#CD000514-bbs2-0095" title="LindleyR . ENCHANTED. Powerpoint presentation. ">ENCHANTED</a>; <a href="./references#CD000514-bbs2-0096" title="TrouillasP , NighoghossianN , DerexL , AdeleineP . FRALYSE, a randomised blind multicenter study comparing 0.9mg/kg for 60 minutes and 0.8mg/kg for 90 minutes in a 7 hour window. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy; 27‐28 May 2002; Lyon, France. 2002:74. ">FRALYSE</a>; <a href="./references#CD000514-bbs2-0097" title="WangY . ITAIS. Imaging‐based thrombolysis trial in acute ischemic stroke. Internet Stroke Center. WangY , JiangW , LiaoX , DuB , ZhaoX , DongK , et al. Comparison of intravenous and intra‐arterial with tPA within 3‐6 hours guided by multi‐MRI: randomised study of 36 patients. Stroke2008;39:602. WangY , JiangW , ZhaoX , DuB , DongK , LiaoX , et al. Imaging‐based thrombolysis trial in acute ischemic stroke. http://www.abstractsonline.com/arch/RecordPrintView.aspx?LookupKey=12345&amp;RecordID=17703. 2007. ">ITAIS</a>) are classified as ongoing . One further study (<a href="./references#CD000514-bbs2-0092" title="WadiaRS . Clinical trial to assess the efficacy and safety of TNK‐TPA in acute ischemic stroke. Clinical Trials Registry ‐ India (CTRI) http://www.ctri.in2009. ">Wadia 2009</a>) appears relevant to the topic of this review as it tests two different doses of tenecteplase but it has only been published in abstract so far and further information is required, particularly regarding the method of randomisation, and is therefore classified as awaiting evaluation. </p> </section> <section id="CD000514-sec3-0019"> <h4 class="title">Included studies</h4> <p>We included 20 trials involving 2527 patients, of which 13 trials (1433 patients) were relevant to the comparison of higher dose with lower dose, five trials (875 patients) to one agent versus another and five trials (485 patients) to different routes of administration. Three of these trials (<a href="./references#CD000514-bbs2-0002" title="AbeT , TerashiA , TohgiH , et al. Clinical efficacy of intravenous administration of SM‐9527 (t‐PA) in cerebral thrombolysis ‐ multi‐centre double‐blind study in comparison with urokinase. Clinical Evaluation1990;18:39‐69. YamaguchiT , HayakawaT , KikuchiH , AbeT . Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: HackeW , delZoppoGJ , HirschbergM editor(s). Thrombolytic Therapy in Acute Ischaemic Stroke. 1st Edition. Berlin: Spinger‐Verlag, 1990:168‐9. ">Abe 1990</a>; <a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>) compared both different doses (259 patients) and different agents (341 patients). Thus, there was an overlap for the number of included trials and patients. Summary details of the included trials are given in the <a href="./references#CD000514-sec2-0016" title="">Characteristics of included studies</a> table including, where available, data on baseline characteristics of the included patients. </p> <p>Thirteen trials compared a higher dose of a thrombolytic drug with a lower dose of the same drug, of which five trials (<a href="./references#CD000514-bbs2-0002" title="AbeT , TerashiA , TohgiH , et al. Clinical efficacy of intravenous administration of SM‐9527 (t‐PA) in cerebral thrombolysis ‐ multi‐centre double‐blind study in comparison with urokinase. Clinical Evaluation1990;18:39‐69. YamaguchiT , HayakawaT , KikuchiH , AbeT . Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: HackeW , delZoppoGJ , HirschbergM editor(s). Thrombolytic Therapy in Acute Ischaemic Stroke. 1st Edition. Berlin: Spinger‐Verlag, 1990:168‐9. ">Abe 1990</a>; <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>; <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>; <a href="./references#CD000514-bbs2-0013" title="OhtomoE , et al. Clinical efficacy of AK‐124 (tissue plasminogen activator) in the treatment of cerebral thrombosis ‐ dose‐finding study by means of multi‐center double blind comparison. Yakuri to Chiryo (Pharmacology and Therapy)1988;16(5):327‐53. ">Ohtomo 1988a</a>; <a href="./references#CD000514-bbs2-0020" title="WangSY , WangXL , ZengH , ZuoY , HuN , Li XY , et al. Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction. Chinese Critical Care Medicine2003;15(9):542‐5. WangXL , ZengH , FanK , WangKY , ZuoY , WangSY , et al. Clinical study on early intravenous thrombolysis with rt‐PA for acute cerebral infarction. Chinese Journal of Neurology2006;39(10):678‐83. ZengH , WangX , QiX , WangH . Thrombolytic therapy using actilyse (rt‐PA) in patients with acute cerebral infarction. Chinese Journal of Emergency Medicine2006;15(5):457‐9. ">Wang 2003</a>) tested t‐PA, three trials (<a href="./references#CD000514-bbs2-0001" title="AbeT , KazamaM , NaitoI , et al. Clinical effect of urokinase (60 000 units/day) on cerebral infarction ‐ comparative study by means of multiple center double blind test. Blood and Vessel1981;12:342‐58. ">Abe 1981</a>; <a href="./references#CD000514-bbs2-0003" title="UK‐BR Study Group (Atarashi J, OhtomoE , ArakiG , ItohE , TogiH , MatsudaT) . Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis ‐ multi‐center double blind study in comparison with placebo. Clinical Evaluation1985;13:659‐709. ">Atarashi 1985</a>; <a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a>) tested UK, three trials (<a href="./references#CD000514-bbs2-0005" title="FurlanAJ , EydingD , AlbersGW , Al‐RawiY , LeesKR , RowleyHA , et al. Dose Escalation of Desmoteplase for Acute ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke2006;37(5):1227‐31. ">DEDAS</a>; <a href="./references#CD000514-bbs2-0006" title="FiebachJB , Al‐RawiY , WintermarkM , FurlanAJ , HackeW , RowleyHA , et al. Vascular occlusion as imaging biomarker in selecting acute ischaemic stroke patients for treatment with desmoteplase. Cerebrovascular Diseases2011;31 Suppl 2:165. ForestLaboratories . Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS‐2). ClinicalTrials.gov2005. HackeW , FurlanAJ , Al‐RawiY , DavalosA , FiebachJB , GruberF , et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion‐diffusion weighted imaging or perfusion CT (DIAS‐2): a prospective, randomised, double‐blind, placebo‐controlled study. Lancet Neurology2009;8:141‐50. ">DIAS‐2</a>; <a href="./references#CD000514-bbs2-0007" title="HackeW , AlbersG , Al‐RawiY , BogousslavskyJ , DavalosA , EliasziwM , et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI‐based 9‐hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke2005;36(1):66‐73. ">DIAS 2005</a>) tested desmoteplase, and two trials (<a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>) tested tenecteplase. Two trials (<a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>; <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>) compared rt‐PA (duteplase) 30 MIU (equivalent to 60 mg alteplase) with 20 MIU (40 mg) given by intravenous infusion for one hour. <a href="./references#CD000514-bbs2-0002" title="AbeT , TerashiA , TohgiH , et al. Clinical efficacy of intravenous administration of SM‐9527 (t‐PA) in cerebral thrombolysis ‐ multi‐centre double‐blind study in comparison with urokinase. Clinical Evaluation1990;18:39‐69. YamaguchiT , HayakawaT , KikuchiH , AbeT . Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: HackeW , delZoppoGJ , HirschbergM editor(s). Thrombolytic Therapy in Acute Ischaemic Stroke. 1st Edition. Berlin: Spinger‐Verlag, 1990:168‐9. ">Abe 1990</a> compared rt‐PA 2 MU with 1 MU/day intravenously over one hour once per day for seven days. <a href="./references#CD000514-bbs2-0013" title="OhtomoE , et al. Clinical efficacy of AK‐124 (tissue plasminogen activator) in the treatment of cerebral thrombosis ‐ dose‐finding study by means of multi‐center double blind comparison. Yakuri to Chiryo (Pharmacology and Therapy)1988;16(5):327‐53. ">Ohtomo 1988a</a> compared t‐PA 60,000 U with 36,000 U/day intravenously over one hour once per day for seven days. <a href="./references#CD000514-bbs2-0001" title="AbeT , KazamaM , NaitoI , et al. Clinical effect of urokinase (60 000 units/day) on cerebral infarction ‐ comparative study by means of multiple center double blind test. Blood and Vessel1981;12:342‐58. ">Abe 1981</a> compared 60,000 U UK/day with 6000 U, <a href="./references#CD000514-bbs2-0003" title="UK‐BR Study Group (Atarashi J, OhtomoE , ArakiG , ItohE , TogiH , MatsudaT) . Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis ‐ multi‐center double blind study in comparison with placebo. Clinical Evaluation1985;13:659‐709. ">Atarashi 1985</a> compared 240,000 U UK per day with 60,000 U/day ‐ in both trials the UK was given intravenously over one hour once per day for seven days. Only <a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a> used UK in doses of 1 million units compared to 1.5 million units given within 30 minutes, i.e. in a manner compatible with other recent trials testing thrombolysis versus placebo in acute ischaemic stroke. In the case of the DIAS study where more than two regimens were evaluated, only the doses 125 µg/kg versus 90 µg/kg have been included in the analysis. The small numbers in the other dose groups make further statistical analysis meaningless at this stage. In <a href="./references#CD000514-bbs2-0005" title="FurlanAJ , EydingD , AlbersGW , Al‐RawiY , LeesKR , RowleyHA , et al. Dose Escalation of Desmoteplase for Acute ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke2006;37(5):1227‐31. ">DEDAS</a> there were 12 protocol violations (six had no perfusion diffusion mismatch and six had internal carotid artery occlusions, which was an exclusion criterion; two in the placebo group, six in the low‐dose and four in the high‐dose group); for the purpose of this review we included these patients in the analysis. The DIAS study was a phase II dose finding study and several doses were tested; in the data analysis in this review we have only included the doses 125 µg/kg versus 90 µg/kg. In the two trials of tenecteplase (<a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>) the dose 0.25 mg/kg TNK is defined as the high‐dose group and the 0.1 mg/kg TNK as the low‐dose group. The 0.4 mg/kg TNK group in <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a> had the lowest numbers, was eliminated early from the trial as inferior to the other two and has not been included in the statistical results. </p> <p>Five trials tested different drugs ‐ two compared t‐PA with UK (<a href="./references#CD000514-bbs2-0002" title="AbeT , TerashiA , TohgiH , et al. Clinical efficacy of intravenous administration of SM‐9527 (t‐PA) in cerebral thrombolysis ‐ multi‐centre double‐blind study in comparison with urokinase. Clinical Evaluation1990;18:39‐69. YamaguchiT , HayakawaT , KikuchiH , AbeT . Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: HackeW , delZoppoGJ , HirschbergM editor(s). Thrombolytic Therapy in Acute Ischaemic Stroke. 1st Edition. Berlin: Spinger‐Verlag, 1990:168‐9. ">Abe 1990</a>; <a href="./references#CD000514-bbs2-0014" title="OhtomoE , et al. Clinical efficacy of AK ‐124 (tissue plasminogen activator) in the treatment of cerebral thrombosis ‐ study by means of multi‐center double blind comparison with urokinase. Pharmacology and Therapy1988;16(9):167‐213. ">Ohtomo 1988b</a>), one compared tissue‐cultured UK with UK (<a href="./references#CD000514-bbs2-0012" title="OhtomoE , ArakiG , ItohE , ToghiH , MatsudaT , AtarashiJ . Clinical efficacy of urokinase in patients with cerebral thrombosis ‐ multicentre double blind study. Kiso‐to‐Rinshyo (Basic and Clinical)1985;19:445‐78. ">Ohtomo 1985</a>) and two tested different doses of tenecteplase with rt‐PA (<a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>). Abe (<a href="./references#CD000514-bbs2-0002" title="AbeT , TerashiA , TohgiH , et al. Clinical efficacy of intravenous administration of SM‐9527 (t‐PA) in cerebral thrombolysis ‐ multi‐centre double‐blind study in comparison with urokinase. Clinical Evaluation1990;18:39‐69. YamaguchiT , HayakawaT , KikuchiH , AbeT . Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: HackeW , delZoppoGJ , HirschbergM editor(s). Thrombolytic Therapy in Acute Ischaemic Stroke. 1st Edition. Berlin: Spinger‐Verlag, 1990:168‐9. ">Abe 1990</a>) compared a higher dose of rt‐PA with a lower dose of t‐PA and with UK. We have used the data from the higher‐dose (2 MU/day) rt‐PA group to compare with the UK group (60,000 IU) because of their dose similarity (as judged by dose equivalence for the treatment of acute MI). The tenecteplase trials (<a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>) compared two or three different doses of tenecteplase as well as rt‐PA with tenecteplase. We extracted data comparing rt‐PA against all doses of TNK as the optimal dose of TNK in the treatment of stroke is not known at this stage and the analysis could be updated in the future in the light of further evidence. </p> <p>Five trials compared two different routes of administration, four (<a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>; <a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a>; <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>; <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>) tested rt‐PA and one (<a href="./references#CD000514-bbs2-0008" title="DucrocqX , AnxionnatR , TaillandierL , LacourJC , BracardS , BollaertPE , et al. Intravenous versus intra‐arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovascular Diseases2000;10(Suppl 2):76. DucrocqX , BracardS , TaillandierL , AnxionnatR , LacourJ‐C , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients. Unpublished2001. DucrocqX , BracardS , Taillandier , AnxionnatR , LacourJC , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients. Journal of Neuroradiology2005;32:26‐32. ">Ducrocq 2005</a>) tested UK. The EMS Bridging Trial compared intravenous rt‐PA plus intra‐arterial rt‐PA with intravenous placebo plus intra‐arterial rt‐PA in a pilot study of 35 patients (<a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>). <a href="./references#CD000514-bbs2-0008" title="DucrocqX , AnxionnatR , TaillandierL , LacourJC , BracardS , BollaertPE , et al. Intravenous versus intra‐arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovascular Diseases2000;10(Suppl 2):76. DucrocqX , BracardS , TaillandierL , AnxionnatR , LacourJ‐C , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients. Unpublished2001. DucrocqX , BracardS , Taillandier , AnxionnatR , LacourJC , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients. Journal of Neuroradiology2005;32:26‐32. ">Ducrocq 2005</a> is a single‐centre, randomised trial comparing intravenous versus intra‐arterial UK and had enrolled 27 patients before the study was terminated early due to the high mortality rate. <a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a> conducted a feasibility study comparing intravenous (N = 4) versus intra‐arterial (N = 3) rt‐PA in patients with acute ischaemic stroke and major vessel occlusion on CT angiogram. <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a> was another pilot study evaluating intra‐arterial t‐PA up to six hours (N = 25 participants randomised, 19 treated) versus intravenous t‐PA up to three hours (N = 29 participants randomised, 28 treated). Mechanical thrombus disruption or clot retrieval was allowed (used in 8/19 patients) but not balloon angioplasty. <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a> (N = 362), similar to like <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>, compared intra‐arterial with intravenous rt‐PA up to 4.5 hours after stroke. Mechanical devices were allowed (in patients allocated intra‐arterial therapy, 109/181 had clot fragmentation with a guidewire in addition to rt‐PA and a device was used in 56/181 patients). The technique of thrombolytic delivery, mechanical clot disruption or clot extraction and the exact dose of fibrinolytic agent may differ substantially between patients, operators and trials. However, such differences are difficult to account for in the statistical analysis, especially when the data are so scant. The rt‐PA in the <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a> and <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a> trials was administered as an infusion while in the other two newly included studies the thrombolytic agent was administered with what is described as the 'pulse spray' method. Whether or not this makes a practical difference is not known. Different doses of heparin are routinely administered during the intra‐arterial treatment, further confounding the results. Blinding of patients and doctors to treatment is challenging in the interventional studies, increasing the risk for further bias. </p> </section> <section id="CD000514-sec3-0020"> <h4 class="title">Excluded studies</h4> <p>We excluded 71 studies because they were either: irrelevant to the current review, lacked randomisation or were confounded by the use of additional agents such as ultrasound or other drugs (see details below and the <a href="./references#CD000514-sec2-0017" title="">Characteristics of excluded studies</a> table). We excluded some studies because they were confounded by different time windows (<a href="./references#CD000514-bbs2-0026" title="BuX , HuangY , ZhaoY , ZhangX , SuS , PingB . Study on treatment time window for intravenous thrombolysis of acute ischaemic stroke. Modern Diagnosis and Treatment (Xian dai zhen duan yu zhi liao)1998;9(5):267‐9. ">Bu 1998</a>; <a href="./references#CD000514-bbs2-0050" title="LeeJH , SeoDC , KimJS , LeeMC . Therapeutic efficacy of urokinase and heparin in acute ischaemic stroke. Stroke1994;25:268. ">Lee 1994</a>), or confounded by concomitant heparin doses (<a href="./references#CD000514-bbs2-0074" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Therapeutic effect of thrombin inhibitor MD‐805 in cerebral thrombosis ‐ double blinded comparative study with tissue cultured urokinase. Igaku no Ayumi1987;141:499‐515. ">Tazaki 1987</a>; <a href="./references#CD000514-bbs2-0076" title="TsuchiyaT , FujikakeK , OkuK . Effects of urokinase and heparin on hemorrhagic infarction, recanalization, recurrence ‐ analysis of 111 cases with middle cerebral artery occlusion on an acute stage in a prospective controlled trial. Japanese Journal of Stroke1989;11:500‐10. ">Tsuchiya 1989</a>; <a href="./references#CD000514-bbs2-0077" title="TsuchiyaT , FujikakeK , OkuK . A study on clinical effects of the combinated therapy of urokinase and heparin for acute lacunar infarcts in a prospective controlled trial. Japanese Journal of Stroke1990;11:177‐84. ">Tsuchiya 1990</a>), or were stopped after only a few patients had been included (<a href="./references#CD000514-bbs2-0068" title="RiedelA . Phase II pilot study of pro‐urokinase (Saruplase) in acute stroke with angiographically‐proven occlusion of the middle cerebral artery. Unpublished. ">Riedel 1996</a>), or were studies of haematological effects of thrombolysis with no clinical outcome assessments (<a href="./references#CD000514-bbs2-0036" title="GaoQL , HanQY , LiBS . Comparative observation of urokinase injected by carotid and peripheral vein treating brain infarction. Journal of Clinical Medicine (Lin chuang nei ke za zhi)1994;11(2):38‐9. ">Gao 1994</a>; <a href="./references#CD000514-bbs2-0074" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Therapeutic effect of thrombin inhibitor MD‐805 in cerebral thrombosis ‐ double blinded comparative study with tissue cultured urokinase. Igaku no Ayumi1987;141:499‐515. ">Tazaki 1987</a>; <a href="./references#CD000514-bbs2-0086" title="XuH‐Q , ShaoB , ZhouC‐Y . Comparison of the curative effects between ahylsantinfarctase and defibrinogenase on cerebral infarction. Journal of Wenzhou Medical College2000;30(2):124‐6. ">Xu 2000</a>). The six non‐randomised dose‐escalation studies were <a href="./references#CD000514-bbs2-0031" title="Del Zoppo GJ for the rt‐PA Acute Stroke Group. An open multicenter trial of rt‐PA in acute stroke (safety and efficacy): a progress report. Fibrinolysis1990;4 Suppl 3:18 (Abst 47). DelZoppoGJ , PoeckK , PessinMS , FurlanA , ZivinJ , KaseC , et al. An open multicentre trial of rt‐PA in acute stroke: safety and efficacy. Thrombosis and Haemostasis1989;62(1):27. ">Del Zoppo 1989</a>, <a href="./references#CD000514-bbs2-0063" title="MorrisDC , MitsiasP , SilverB , ZhangL , DaleyS , LewandowskiC , et al. Abciximab and rt‐PA in acute ischaemic stroke treatment. Proceedings of the 28th AHA International Stroke Conference; February 13‐15 2003; USA, Phoenix, Arizona: The American Stroke Association. Abstract CTP16. 2003. ">Morris 2003</a>, <a href="./references#CD000514-bbs2-0065" title="QureshiAI . Safety and efficacy of intra‐arterial reteplase and intravenous abciximab in patients with acute ischaemic stroke. www.strokecenter.org2002. ">Qureshi 2002</a>, <a href="./references#CD000514-bbs2-0067" title="Patient Recruitment and Public Liaison Office. ReoPro Retavase Reperfusion of Stroke Safety Study ‐ Imaging Evaluation. www.strokecenter.org (Internet Stroke Center)2002. ">ReoPro Retavase MRI</a>, <a href="./references#CD000514-bbs2-0073" title="HaleyEC . Pilot study of TNK‐TPA in acute ischaemic stroke, treated within 3 hours. CRISP Database (electronic), also Internet Stroke Trials Directory www.strokecenter.org2002. LydenP , on behalf of the TNK for Stroke Investigators. Pilot study of tenecteplase (TNK) in acute ischaemic stroke: preliminary report. Stroke2003;34:246. ">TASS</a> and <a href="./references#CD000514-bbs2-0088" title="YonedaY , MoriE , UeharaT , TabuchiM . Intracarotid regional infusion of recombinant tissue plasminogen activator for acute hemispheric stroke. Cerebrovascular Diseases1998;8:357‐9. ">Yoneda 1998</a>. Two trials (<a href="./references#CD000514-bbs2-0048" title="KontaY , AizuK , Fuziwara , MatsuiT . Evaluation of intravenous urokinase, ozagrel sodium and low molecular dextran therapy in acute ischaemic stroke ‐ comparison of infusion methods of urokinase. Cerebrovascular Diseases1996;6:187. ">Konta 1996</a>; <a href="./references#CD000514-bbs2-0084" title="WuX . Urokinase therapy in acute ischaemic stroke. Proceedings of the 4th Chinese Stroke Conference, Chengdu, China. 1995:149‐50. ">Wu 1995</a>), which were awaiting assessment, have now been excluded because, to the best of our knowledge, the data have still not been published in full after five years. </p> <p>In the process of doing this update we identified several studies that are relevant to the topic of this review but we excluded them because they did not fulfil the inclusion criteria. For example, <a href="./references#CD000514-bbs2-0078" title="ChaoAC , HsuHY , ChungCP , LiuCH , ChenCH , TengMM , et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT‐AIS) study. Stroke2010;41(5):885‐90. ">TTT‐AIS</a> compares two different doses of rt‐PA (standard dose 0.90 mg/kg versus 0.72 mg/kg), but it is not a randomised study. <a href="./references#CD000514-bbs2-0044" title="YamaguchiT , MoriE , MinematsuK , NakagawaraJ , HashiK , SaitoI , et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J‐ACT). Stroke2006;37(7):1810‐5. ">J‐ACT</a> tests the efficacy of 0.6 mg/kg rt‐PA in acute stroke in the Japanese population (contrary to the widely used 0.9 mg/kg); we also excluded this single‐arm, non‐randomised trial, and a further registry (<a href="./references#CD000514-bbs2-0045" title="NakagawaraJ , MinematsuK , OkadaY , TanahashiN , NagahiroS , MoriE , et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post‐Marketing Alteplase Registration Study (J‐MARS). Stroke2010;41:1984‐9. ">J‐MARS 2010</a>), from the review. <a href="./references#CD000514-bbs2-0042" title="WangY , LiaoX , ZhaoX , WangC , LiuL , ZhouY , et al. Imaging‐based thrombolysis trial in acute ischemic stroke‐II (ITAIS‐II). International Journal of Stroke2009;4:49‐53. ">ITAIS‐II</a> is testing the use of CT perfusion and angiography imaging to select patients for thrombolysis but is not a randomised drug comparison. Microplasmin (<a href="./references#CD000514-bbs2-0062" title="ThijsVN , PeetersA , VoskoM , AichnerF , SchellingerPD , SchneiderD , et al. Randomized, placebo‐controlled, dose‐ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke2009;40(12):3789‐95. ">MITI‐IV</a>) is a truncated form of plasmin, has an extremely short half life when given intravenously and is not considered to be a true thrombolytic drug, so we also excluded it. </p> </section> </section> <section id="CD000514-sec2-0009"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias in included studies is summarised in <a href="#CD000514-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD000514-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000514-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD000514-sec3-0021"> <h4 class="title">Allocation</h4> <p>Details about concealment of randomisation were generally scant, so it is difficult to tell how adequate this was. All older trials used sequentially numbered containers for randomisation except two trials (<a href="./references#CD000514-bbs2-0001" title="AbeT , KazamaM , NaitoI , et al. Clinical effect of urokinase (60 000 units/day) on cerebral infarction ‐ comparative study by means of multiple center double blind test. Blood and Vessel1981;12:342‐58. ">Abe 1981</a>; <a href="./references#CD000514-bbs2-0002" title="AbeT , TerashiA , TohgiH , et al. Clinical efficacy of intravenous administration of SM‐9527 (t‐PA) in cerebral thrombolysis ‐ multi‐centre double‐blind study in comparison with urokinase. Clinical Evaluation1990;18:39‐69. YamaguchiT , HayakawaT , KikuchiH , AbeT . Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: HackeW , delZoppoGJ , HirschbergM editor(s). Thrombolytic Therapy in Acute Ischaemic Stroke. 1st Edition. Berlin: Spinger‐Verlag, 1990:168‐9. ">Abe 1990</a>), in which it was unclear whether the containers were sequentially numbered or not. Some of the more recent trials used central telephone randomisation (<a href="./references#CD000514-bbs2-0005" title="FurlanAJ , EydingD , AlbersGW , Al‐RawiY , LeesKR , RowleyHA , et al. Dose Escalation of Desmoteplase for Acute ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke2006;37(5):1227‐31. ">DEDAS</a>; <a href="./references#CD000514-bbs2-0007" title="HackeW , AlbersG , Al‐RawiY , BogousslavskyJ , DavalosA , EliasziwM , et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI‐based 9‐hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke2005;36(1):66‐73. ">DIAS 2005</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>) though others used sealed pre‐packed drugs or sequential numbered envelopes. </p> </section> <section id="CD000514-sec3-0022"> <h4 class="title">Blinding</h4> <p>Most trials were double‐blind so patients and doctors (including the outcome assessors) who treated the patients were blinded. However, some trials were open‐label (<a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a>; <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>; <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>) or conducted in few centres with local outcome assessors (<a href="./references#CD000514-bbs2-0008" title="DucrocqX , AnxionnatR , TaillandierL , LacourJC , BracardS , BollaertPE , et al. Intravenous versus intra‐arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovascular Diseases2000;10(Suppl 2):76. DucrocqX , BracardS , TaillandierL , AnxionnatR , LacourJ‐C , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients. Unpublished2001. DucrocqX , BracardS , Taillandier , AnxionnatR , LacourJC , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients. Journal of Neuroradiology2005;32:26‐32. ">Ducrocq 2005</a>), making it difficult to blind the clinical outcomes to treatment allocation even if the assessments were said to be performed without knowledge of treatment allocation. In <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>, 90‐day follow‐up was by a single neurologist by telephone blinded to treatment allocation. </p> </section> <section id="CD000514-sec3-0023"> <h4 class="title">Incomplete outcome data</h4> <p>After consultation with the trial authors, we excluded few studies because of missing data where the data had been collected in the first place. A more major problem was that many trials did not collect data on functional outcome or symptomatic intracerebral haemorrhage and we therefore excluded them. Details of these are listed in the relevant sections. Most of these studies were small and likely to be methodologically weak for other reasons. </p> </section> <section id="CD000514-sec3-0024"> <h4 class="title">Selective reporting</h4> <p>We did not find any evidence of selective reporting bias.</p> </section> <section id="CD000514-sec3-0025"> <h4 class="title">Other potential sources of bias</h4> <p>No serious imbalance in baseline prognostic factors was reported between treatment groups, although in two trials there were more male patients in the lower‐dose group, and in one trial (<a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>) there were more severe strokes and occluded arteries on angiography in the patients randomised to intravenous plus intra‐arterial rt‐PA than to intravenous placebo plus intra‐arterial rt‐PA. Intention‐to‐treat analyses were not reported in all trials but the data in all trials were sufficient to allow us to perform an intention‐to‐treat analysis in this review. </p> <section id="CD000514-sec4-0003"> <h5 class="title">Other methodological factors</h5> <p>There is marked heterogeneity in the included studies as practices have changed over the last 30 years. The trial methodology and published data of the studies included in the last update are more standardised when compared with the earlier studies of this review: they now typically contain basic information on baseline stroke characteristics and the 90‐day modified Rankin Scale. Seven of the early trials aimed to include patients with cerebral thrombosis, but most did not define what that was. One trial (<a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>) aimed to include thromboembolic stroke (source unspecified) of the internal carotid artery territory. Two trials used intra‐arterial angiography to document the presence of thrombus in a cerebral artery (<a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>; <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>). One trial (<a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>) aimed to include only patients with cerebral embolism (source unspecified). All the patients had a CT brain scan to exclude intracranial haemorrhage prior to randomisation. Most trials (<a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a>; <a href="./references#CD000514-bbs2-0008" title="DucrocqX , AnxionnatR , TaillandierL , LacourJC , BracardS , BollaertPE , et al. Intravenous versus intra‐arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovascular Diseases2000;10(Suppl 2):76. DucrocqX , BracardS , TaillandierL , AnxionnatR , LacourJ‐C , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients. Unpublished2001. DucrocqX , BracardS , Taillandier , AnxionnatR , LacourJC , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients. Journal of Neuroradiology2005;32:26‐32. ">Ducrocq 2005</a>; <a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>; <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>; <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>; <a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a>; <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>; <a href="./references#CD000514-bbs2-0020" title="WangSY , WangXL , ZengH , ZuoY , HuN , Li XY , et al. Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction. Chinese Critical Care Medicine2003;15(9):542‐5. WangXL , ZengH , FanK , WangKY , ZuoY , WangSY , et al. Clinical study on early intravenous thrombolysis with rt‐PA for acute cerebral infarction. Chinese Journal of Neurology2006;39(10):678‐83. ZengH , WangX , QiX , WangH . Thrombolytic therapy using actilyse (rt‐PA) in patients with acute cerebral infarction. Chinese Journal of Emergency Medicine2006;15(5):457‐9. ">Wang 2003</a>) entered patients within six hours of stroke onset. Three studies (<a href="./references#CD000514-bbs2-0005" title="FurlanAJ , EydingD , AlbersGW , Al‐RawiY , LeesKR , RowleyHA , et al. Dose Escalation of Desmoteplase for Acute ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke2006;37(5):1227‐31. ">DEDAS</a>; <a href="./references#CD000514-bbs2-0006" title="FiebachJB , Al‐RawiY , WintermarkM , FurlanAJ , HackeW , RowleyHA , et al. Vascular occlusion as imaging biomarker in selecting acute ischaemic stroke patients for treatment with desmoteplase. Cerebrovascular Diseases2011;31 Suppl 2:165. ForestLaboratories . Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS‐2). ClinicalTrials.gov2005. HackeW , FurlanAJ , Al‐RawiY , DavalosA , FiebachJB , GruberF , et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion‐diffusion weighted imaging or perfusion CT (DIAS‐2): a prospective, randomised, double‐blind, placebo‐controlled study. Lancet Neurology2009;8:141‐50. ">DIAS‐2</a>; <a href="./references#CD000514-bbs2-0007" title="HackeW , AlbersG , Al‐RawiY , BogousslavskyJ , DavalosA , EliasziwM , et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI‐based 9‐hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke2005;36(1):66‐73. ">DIAS 2005</a>) extended this window to nine hours if there was more than 20% potentially salvageable tissue suggested by perfusion imaging (CT or MR). Five trials entered patients within three to five days and one trial (<a href="./references#CD000514-bbs2-0001" title="AbeT , KazamaM , NaitoI , et al. Clinical effect of urokinase (60 000 units/day) on cerebral infarction ‐ comparative study by means of multiple center double blind test. Blood and Vessel1981;12:342‐58. ">Abe 1981</a>) within 14 days. One trial (<a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>) excluded patients with visible early infarction on the pre‐randomisation CT scan. One tenecteplase trial (<a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>) only included patients with a perfusion lesion on CT perfusion imaging that was 20% larger than the infarct core and an associated arterial occlusion on CT angiography pre‐randomisation. </p> <p>In the early studies, it was not possible to extract much information on the baseline characteristics of the patients or the relation to treatment outcome. For example, <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a> used the Hemispheric Stroke Scale (HSS) to classify patients at randomisation (32% of the group given 30 MIU t‐PA, and 37% of those given 20 MIU t‐PA, were HSS 1 to 60), but it was not possible to relate these data to outcome following treatment. However, all the new studies included in the latest update contained baseline and post‐treatment characteristics such as stroke severity scores and functional outcome at the end of follow‐up for each treatment group. In the <a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>, there were more patients with severe strokes (and also more patients with occlusive thrombus in the intracranial arteries on angiography) in the patients randomised to intravenous plus intra‐arterial rt‐PA than in those randomised to intravenous placebo plus intra‐arterial rt‐PA (<a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>). In <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>, six of the 25 patients randomised to intra‐arterial thrombolysis did not receive any treatment (no vessel occlusion, five of the six patients improved spontaneously); this compares with one of the 29 patients randomised to intravenous thrombolysis that improved spontaneously. In <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>, 15/181 patients allocated to intra‐arterial treatment did not receive it (six improved clinically, three had no occlusion, three were dissections, one had a bleeding diathesis, one groin haematoma, one due to the delayed arrival of the interventionist) versus 3/181 allocated to intravenous treatment (one spontaneously improved, two had thrombectomy). </p> <p>Antithrombotic drugs were not allowed during the whole study period in five trials (<a href="./references#CD000514-bbs2-0001" title="AbeT , KazamaM , NaitoI , et al. Clinical effect of urokinase (60 000 units/day) on cerebral infarction ‐ comparative study by means of multiple center double blind test. Blood and Vessel1981;12:342‐58. ">Abe 1981</a>; <a href="./references#CD000514-bbs2-0003" title="UK‐BR Study Group (Atarashi J, OhtomoE , ArakiG , ItohE , TogiH , MatsudaT) . Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis ‐ multi‐center double blind study in comparison with placebo. Clinical Evaluation1985;13:659‐709. ">Atarashi 1985</a>; <a href="./references#CD000514-bbs2-0012" title="OhtomoE , ArakiG , ItohE , ToghiH , MatsudaT , AtarashiJ . Clinical efficacy of urokinase in patients with cerebral thrombosis ‐ multicentre double blind study. Kiso‐to‐Rinshyo (Basic and Clinical)1985;19:445‐78. ">Ohtomo 1985</a>; <a href="./references#CD000514-bbs2-0013" title="OhtomoE , et al. Clinical efficacy of AK‐124 (tissue plasminogen activator) in the treatment of cerebral thrombosis ‐ dose‐finding study by means of multi‐center double blind comparison. Yakuri to Chiryo (Pharmacology and Therapy)1988;16(5):327‐53. ">Ohtomo 1988a</a>; <a href="./references#CD000514-bbs2-0014" title="OhtomoE , et al. Clinical efficacy of AK ‐124 (tissue plasminogen activator) in the treatment of cerebral thrombosis ‐ study by means of multi‐center double blind comparison with urokinase. Pharmacology and Therapy1988;16(9):167‐213. ">Ohtomo 1988b</a>) although an exception could be made if the doctors thought that antithrombotic drugs were needed. Antithrombotic drugs were not allowed within the treatment period but could be allowed thereafter in four trials (<a href="./references#CD000514-bbs2-0002" title="AbeT , TerashiA , TohgiH , et al. Clinical efficacy of intravenous administration of SM‐9527 (t‐PA) in cerebral thrombolysis ‐ multi‐centre double‐blind study in comparison with urokinase. Clinical Evaluation1990;18:39‐69. YamaguchiT , HayakawaT , KikuchiH , AbeT . Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: HackeW , delZoppoGJ , HirschbergM editor(s). Thrombolytic Therapy in Acute Ischaemic Stroke. 1st Edition. Berlin: Spinger‐Verlag, 1990:168‐9. ">Abe 1990</a>; <a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>; <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>; <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>). All patients received aspirin 300 mg starting 24 hours after randomisation in <a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a>. No antithrombotics were allowed in the first 24 hours in <a href="./references#CD000514-bbs2-0008" title="DucrocqX , AnxionnatR , TaillandierL , LacourJC , BracardS , BollaertPE , et al. Intravenous versus intra‐arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovascular Diseases2000;10(Suppl 2):76. DucrocqX , BracardS , TaillandierL , AnxionnatR , LacourJ‐C , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients. Unpublished2001. DucrocqX , BracardS , Taillandier , AnxionnatR , LacourJC , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients. Journal of Neuroradiology2005;32:26‐32. ">Ducrocq 2005</a> or <a href="./references#CD000514-bbs2-0007" title="HackeW , AlbersG , Al‐RawiY , BogousslavskyJ , DavalosA , EliasziwM , et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI‐based 9‐hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke2005;36(1):66‐73. ">DIAS 2005</a>. <a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a>, <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a> and <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a> mentioned the use a variable amount of intra‐arterial heparin either as a bolus (<a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>; <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>) or through heparinised flush solution during the interventional treatment (<a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a>). </p> <p>Eight trials used the 'overall neurological improvement rating' and side effects as their main outcome measures. Four of the trials assessed 'utility' (as judged by the neurological improvement and side effects). The others used standard stroke outcome measures: modified Rankin scale (mRS), European Stroke Scale (ESS), Barthel Index (BI). The number of patients who died, or had an intra or extracranial haemorrhage, could be extracted from all trials except one (<a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>) in which extracranial haemorrhage was not reported. Seven trials mentioned activities of daily living (ADL) as part of their overall improvement measure, but most only reported the number of patients with improvements in the ADL score compared with their baseline score. Thus, we were not able to extract the number of dependent patients except from <a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a>, the <a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a> and <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>, which used the BI and mRS to measure functional outcome. <a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a> only describes neurological improvement at three months (defined as reduction in the National Institutes of Health Stroke Scale (NIHSS) score by four or more points) and it was not possible to extract the number of dependent patients at the end of follow‐up. </p> <p>Dependency was differently defined and followed up. <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a> measured the BI at one month after the stroke, but only reported the mean BI for the two treatment groups, not the actual number of dependent patients. <a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a> used a BI less than 95 and a mRS greater than 1, and the <a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a> published details of individual patients' mRS. <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a> and <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a> defined good clinical outcome as mRS of 0 or 1. Where available, we defined death or dependency at the end of follow‐up as mRS 3 to 6 at the latest time interval available. </p> <p>The duration of follow‐up was only one month in eight trials and three months in 12 trials. The one‐month functional outcome might not be relevant to the final true outcome because of insufficient time to allow maximum recovery. </p> </section> </section> </section> <section id="CD000514-sec2-0010"> <h3 class="title" id="CD000514-sec2-0010">Effects of interventions</h3> <p>This results section is split into three parts. The first part deals with direct comparisons of different doses of the same drug, the second part with direct comparisons of different drugs, and the third part with direct comparisons of different routes of administration of the same drug. It was not always possible to assess for statistically significant heterogeneity because of a paucity of trials, but where it was possible to test, none of the outcomes showed any statistically significant heterogeneity. </p> <section id="CD000514-sec3-0026"> <h4 class="title">1. Comparison of higher dose with lower dose of the same drug</h4> <section id="CD000514-sec4-0004"> <h5 class="title">(a) Death or dependency at the end of follow‐up</h5> <p>Seven trials (<a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a>; <a href="./references#CD000514-bbs2-0005" title="FurlanAJ , EydingD , AlbersGW , Al‐RawiY , LeesKR , RowleyHA , et al. Dose Escalation of Desmoteplase for Acute ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke2006;37(5):1227‐31. ">DEDAS</a>; <a href="./references#CD000514-bbs2-0006" title="FiebachJB , Al‐RawiY , WintermarkM , FurlanAJ , HackeW , RowleyHA , et al. Vascular occlusion as imaging biomarker in selecting acute ischaemic stroke patients for treatment with desmoteplase. Cerebrovascular Diseases2011;31 Suppl 2:165. ForestLaboratories . Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS‐2). ClinicalTrials.gov2005. HackeW , FurlanAJ , Al‐RawiY , DavalosA , FiebachJB , GruberF , et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion‐diffusion weighted imaging or perfusion CT (DIAS‐2): a prospective, randomised, double‐blind, placebo‐controlled study. Lancet Neurology2009;8:141‐50. ">DIAS‐2</a>; <a href="./references#CD000514-bbs2-0007" title="HackeW , AlbersG , Al‐RawiY , BogousslavskyJ , DavalosA , EliasziwM , et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI‐based 9‐hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke2005;36(1):66‐73. ">DIAS 2005</a>; <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>; <a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>) provided this outcome (at three months after the stroke, apart from <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a> where the follow‐up was one month) and no statistically significant difference was observed between the higher dose and lower dose groups (OR 0.86, 95% CI 0.62 to 1.19, I² = 27%) (<a href="./references#CD000514-fig-00101" title="">Analysis 1.1</a>). <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a> measured the BI and found no statistically significant difference in the mean BI score between the 20 and the 30 MIU treatment groups (mean BI score 46 versus 49 respectively, P = 0.8). </p> </section> <section id="CD000514-sec4-0005"> <h5 class="title">(b) Death (early and late)</h5> <p>Data for this outcome were available in 10 and 12 trials respectively regarding early (<a href="./references#CD000514-fig-00102" title="">Analysis 1.2</a>) and late deaths (<a href="./references#CD000514-fig-00103" title="">Analysis 1.3</a>). There was no statistically significant difference between the higher and lower‐dose groups in terms of early (OR 1.09, 95% CI 0.66 to 1.80) or total deaths by the end of follow‐up (OR 1.22, 95% CI 0.82 to 1.80, I² = 32%). In patients allocated to the higher versus lower dose of desmoteplase, there were significantly more deaths at the end of the follow‐up (OR 3.21, 95% CI 1.23 to 8.39). </p> </section> <section id="CD000514-sec4-0006"> <h5 class="title">(c) 'Significant' and fatal intracranial haemorrhage</h5> <p>All 13 trials provide data on 'significant' intracranial haemorrhage (<a href="./references#CD000514-fig-00104" title="">Analysis 1.4</a>) and 10 on fatal haemorrhages (<a href="./references#CD000514-fig-00105" title="">Analysis 1.5</a>). <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a> provides only the number of non‐fatal intracranial haemorrhages but not the total symptomatic intracranial haemorrhages within the first two weeks. The definition of 'significant' haemorrhage is not always clear or standardised across the studies. Some trials define symptomatic intracranial haemorrhage (<a href="./references#CD000514-bbs2-0005" title="FurlanAJ , EydingD , AlbersGW , Al‐RawiY , LeesKR , RowleyHA , et al. Dose Escalation of Desmoteplase for Acute ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke2006;37(5):1227‐31. ">DEDAS</a>; <a href="./references#CD000514-bbs2-0006" title="FiebachJB , Al‐RawiY , WintermarkM , FurlanAJ , HackeW , RowleyHA , et al. Vascular occlusion as imaging biomarker in selecting acute ischaemic stroke patients for treatment with desmoteplase. Cerebrovascular Diseases2011;31 Suppl 2:165. ForestLaboratories . Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS‐2). ClinicalTrials.gov2005. HackeW , FurlanAJ , Al‐RawiY , DavalosA , FiebachJB , GruberF , et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion‐diffusion weighted imaging or perfusion CT (DIAS‐2): a prospective, randomised, double‐blind, placebo‐controlled study. Lancet Neurology2009;8:141‐50. ">DIAS‐2</a>; <a href="./references#CD000514-bbs2-0007" title="HackeW , AlbersG , Al‐RawiY , BogousslavskyJ , DavalosA , EliasziwM , et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI‐based 9‐hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke2005;36(1):66‐73. ">DIAS 2005</a>) as intracranial haemorrhage within 72 hours of treatment that led to an increase by four points or more in the NIHSS score. Others (<a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>) define symptomatic haemorrhage as any haemorrhage seen on a follow‐up CT that can explain any neurological worsening (appearance of new deficit or worsening of previous deficit persisting more than eight hours). Some trials (<a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a>; <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>; <a href="./references#CD000514-bbs2-0012" title="OhtomoE , ArakiG , ItohE , ToghiH , MatsudaT , AtarashiJ . Clinical efficacy of urokinase in patients with cerebral thrombosis ‐ multicentre double blind study. Kiso‐to‐Rinshyo (Basic and Clinical)1985;19:445‐78. ">Ohtomo 1985</a>; <a href="./references#CD000514-bbs2-0013" title="OhtomoE , et al. Clinical efficacy of AK‐124 (tissue plasminogen activator) in the treatment of cerebral thrombosis ‐ dose‐finding study by means of multi‐center double blind comparison. Yakuri to Chiryo (Pharmacology and Therapy)1988;16(5):327‐53. ">Ohtomo 1988a</a>; <a href="./references#CD000514-bbs2-0014" title="OhtomoE , et al. Clinical efficacy of AK ‐124 (tissue plasminogen activator) in the treatment of cerebral thrombosis ‐ study by means of multi‐center double blind comparison with urokinase. Pharmacology and Therapy1988;16(9):167‐213. ">Ohtomo 1988b</a>) did not clearly describe the relationship between clinical deterioration and the CT‐confirmed intracranial haemorrhages, but they classified the severity of intracranial haemorrhage as mild, moderate and severe (also not clearly defined). For those studies we collected the number of moderate or worse (or massive or mass effect on CT) as 'significant intracranial haemorrhages'. There were more significant intracranial haemorrhages in the patients allocated to higher doses than lower doses (OR 1.43, 95% CI 0.81 to 2.52, I² = 0%), but the difference was not statistically significant. There were significantly more fatal intracranial haemorrhages in the high‐dose group at the end of follow‐up (OR 2.71, 95% CI 1.22 to 6.04, I² = 0%) although the confidence intervals were wide because of the small number of events. If confirmed in future large trials, this would be equivalent to 23 more fatal intracranial haemorrhages per 1000 patients treated with high versus low‐dose thrombolytic drugs. Despite the failure of some trials to define intracranial haemorrhage in terms of its clinical effect, it was possible to identify important relationships. For example, in <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>, eight of the 13 patients in the group treated with 30 MIU rt‐PA who died were said to have 'cerebral haemorrhage with mass effect' or 'massive cerebral haemorrhage' compared with only one of the 13 patients in the group treated with 20 MIU rt‐PA. </p> </section> <section id="CD000514-sec4-0007"> <h5 class="title">(d) Major extracranial haemorrhage</h5> <p>Nine trials provided these data (<a href="./references#CD000514-fig-00106" title="">Analysis 1.6</a>). There were more major extracranial haemorrhages in the patients allocated to the higher than the lower dose (OR 1.72, 95% CI 0.93 to 3.21) but the difference was not statistically significant. </p> </section> </section> <section id="CD000514-sec3-0027"> <h4 class="title">2. Comparison of one drug with another</h4> <p>Five trials compared one agent with another ‐ one trial of rt‐PA versus UK (<a href="./references#CD000514-bbs2-0002" title="AbeT , TerashiA , TohgiH , et al. Clinical efficacy of intravenous administration of SM‐9527 (t‐PA) in cerebral thrombolysis ‐ multi‐centre double‐blind study in comparison with urokinase. Clinical Evaluation1990;18:39‐69. YamaguchiT , HayakawaT , KikuchiH , AbeT . Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: HackeW , delZoppoGJ , HirschbergM editor(s). Thrombolytic Therapy in Acute Ischaemic Stroke. 1st Edition. Berlin: Spinger‐Verlag, 1990:168‐9. ">Abe 1990</a>), one trial of t‐PA versus UK (<a href="./references#CD000514-bbs2-0014" title="OhtomoE , et al. Clinical efficacy of AK ‐124 (tissue plasminogen activator) in the treatment of cerebral thrombosis ‐ study by means of multi‐center double blind comparison with urokinase. Pharmacology and Therapy1988;16(9):167‐213. ">Ohtomo 1988b</a>), one trial of tissue‐cultured UK versus UK (<a href="./references#CD000514-bbs2-0012" title="OhtomoE , ArakiG , ItohE , ToghiH , MatsudaT , AtarashiJ . Clinical efficacy of urokinase in patients with cerebral thrombosis ‐ multicentre double blind study. Kiso‐to‐Rinshyo (Basic and Clinical)1985;19:445‐78. ">Ohtomo 1985</a>) and two trials of different doses of tenecteplase versus rt‐PA (<a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>). With the limitations described above, we included two trials (<a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a>) in this section comparing the cumulative outcome from two different doses of tenecteplase versus t‐PA. </p> <section id="CD000514-sec4-0008"> <h5 class="title">(a) Death or dependency at the end of follow‐up</h5> <p>Only the tenecteplase trials contribute to this outcome. There was no significant difference in death or dependency at the end of follow‐up between tenecteplase and t‐PA (OR 0.58, 95% CI 0.31 to 1.09) (<a href="./references#CD000514-fig-00201" title="">Analysis 2.1</a>). </p> </section> <section id="CD000514-sec4-0009"> <h5 class="title">(b) Death</h5> <p>All trials reported the number of patients who died and the cause. There was no statistically significant difference in the number of deaths between patients treated with UK and another agent within the first two weeks (tissue‐cultured UK versus UK, OR 1.37, 95% CI 0.23 to 8.09; rt‐PA versus UK, OR 0.90, 95% CI 0.27 to 2.98). The tenecteplase trials did not provide this outcome (<a href="./references#CD000514-fig-00202" title="">Analysis 2.2</a>). There were slightly more deaths by the end of follow‐up (<a href="./references#CD000514-fig-00203" title="">Analysis 2.3</a>) in the patients allocated to tissue‐cultured UK‐treated then in those allocated to UK (OR 1.81, 95% CI 0.36, to 9.19) and slightly fewer deaths in those allocated to rt‐PA than in those allocated to UK (OR 0.72, 95% CI 0.26 to 2.02), but neither comparison was statistically significant. There was a tendency for fewer deaths at the end of follow‐up in those allocated to tenecteplase versus those allocated to rt‐PA, but this did not reach statistical significance (OR 0.52, 95% CI 0.21 to 1.27). </p> </section> <section id="CD000514-sec4-0010"> <h5 class="title">(c) <i>'</i>Significant' and fatal intracranial haemorrhage (the heading 'significant' has been retained for consistency) </h5> <p>This outcome was available in all trials with the exception of the <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a> trial where the number of fatal intracranial haemorrhages could not be extracted from the published data. There was a trend to fewer symptomatic intracranial haemorrhages within the first two weeks in the patients allocated to tissue‐cultured UK or rt‐PA than in those allocated to conventional UK but there were few events (one versus zero and one versus six haemorrhages respectively) and the difference was not statistically significant (OR 0.12, 95% CI 0.0 to 6.21; OR 0.26, 95% CI 0.06 to 1.18 respectively) (<a href="./references#CD000514-fig-00204" title="">Analysis 2.4</a>). Similarly, there was no significant difference in significant intracranial haemorrhage between those allocated tenecteplase or t‐PA (OR 0.74, 95% CI  0.20 to 2.76). There were no fatal haemorrhages in the tissue‐cultured UK versus UK comparison and only one fatal intracranial haemorrhage during the whole study period in the UK versus rt‐PA comparison (OR 7.91, 95% CI 0.16 to 399.54) and only two fatal intracerebral haemorrhages in the TNK versus rt‐PA comparison in one tenecteplase trial (<a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>; OR 0.47, 95% CI 0.02 to 9.02) (<a href="./references#CD000514-fig-00205" title="">Analysis 2.5</a>). </p> </section> <section id="CD000514-sec4-0011"> <h5 class="title">(d) Major extracranial haemorrhage</h5> <p>There were no major extracranial haemorrhages in the tissue‐cultured UK versus UK comparison (<a href="./references#CD000514-fig-00206" title="">Analysis 2.6</a>). Only one non‐fatal event occurred in each group in the UK versus rt‐PA comparison (OR 1.07, 95% CI 0.07 to 17.17). There was one major extracranial non‐fatal haemorrhage in the tenecteplase group versus none in the rt‐PA group in the <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a> trial (OR 3.99, 95% CI 0.05 to 318.43) but extracranial haemorrhage was not reported in <a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>. No fatal events occurred. </p> </section> </section> <section id="CD000514-sec3-0028"> <h4 class="title">3. Comparison of different routes of administration of the same drug</h4> <p>There are five studies in this category, four comparing intravenous versus intra‐arterial rt‐PA (<a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>; <a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a>; <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>; <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>) and one comparing intravenous versus intra‐arterial UK (<a href="./references#CD000514-bbs2-0008" title="DucrocqX , AnxionnatR , TaillandierL , LacourJC , BracardS , BollaertPE , et al. Intravenous versus intra‐arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovascular Diseases2000;10(Suppl 2):76. DucrocqX , BracardS , TaillandierL , AnxionnatR , LacourJ‐C , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients. Unpublished2001. DucrocqX , BracardS , Taillandier , AnxionnatR , LacourJC , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients. Journal of Neuroradiology2005;32:26‐32. ">Ducrocq 2005</a>). Only one trial compares a combination of intravenous rt‐PA plus intra‐arterial rt‐PA with intravenous placebo plus intra‐arterial rt‐PA (<a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>). The <a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a> only included 35 patients and had an imbalance in baseline stroke severity which did not reach conventional statistical significance but which may, none the less, have influenced the outcomes in the two treatment arms in favour of intravenous placebo plus intra‐arterial rt‐PA. <a href="./references#CD000514-bbs2-0008" title="DucrocqX , AnxionnatR , TaillandierL , LacourJC , BracardS , BollaertPE , et al. Intravenous versus intra‐arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovascular Diseases2000;10(Suppl 2):76. DucrocqX , BracardS , TaillandierL , AnxionnatR , LacourJ‐C , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients. Unpublished2001. DucrocqX , BracardS , Taillandier , AnxionnatR , LacourJC , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients. Journal of Neuroradiology2005;32:26‐32. ">Ducrocq 2005</a> is a single‐centre, randomised trial comparing intravenous versus intra‐arterial urokinase: 900,000 units of UK were given within six hours of stroke onset to 27 patients intravenously or intra‐arterially (or less in the intra‐arterial group if recanalisation had been achieved). The study was terminated early due to a high mortality rate. <a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a> performed a feasibility study comparing intravenous (N = 4) versus intra‐arterial (N = 3) t‐PA in patients with acute ischaemic stroke who could start treatment within three hours of symptom onset and had evidence of major arterial occlusion on CT angiogram. <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a> was another pilot study evaluating intra‐arterial t‐PA up to six hours (N = 25 patients randomised, 19 treated) versus intravenous t‐PA up to three hours (N = 29 patients randomised, 28 treated). Mechanical thrombus disruption or clot retrieval was allowed (used in 8/19 patients) but not balloon angioplasty. <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a> was a larger trial of intravenous (N = 181) versus intra‐arterial (N = 181) rt‐PA up to 4.5 hours after ischaemic stroke. Mechanical devices were allowed in addition to intra‐arterial rt‐PA and were used in 56/181 patients. </p> <section id="CD000514-sec4-0012"> <h5 class="title">(a) Death or dependency at the end of follow‐up</h5> <p>Four trials provided these data (<a href="./references#CD000514-bbs2-0008" title="DucrocqX , AnxionnatR , TaillandierL , LacourJC , BracardS , BollaertPE , et al. Intravenous versus intra‐arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovascular Diseases2000;10(Suppl 2):76. DucrocqX , BracardS , TaillandierL , AnxionnatR , LacourJ‐C , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients. Unpublished2001. DucrocqX , BracardS , Taillandier , AnxionnatR , LacourJC , GuilleminF , et al. Comparison of intravenous and intra‐arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients. Journal of Neuroradiology2005;32:26‐32. ">Ducrocq 2005</a>; <a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>; <a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>; <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>). The fifth study (<a href="./references#CD000514-bbs2-0016" title="SenS , HuangDY , AkhavenO , WilsonS , VerroP , SolanderS . IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocritical Care2009;11:76‐81. ">Sen 2008</a>) only describes neurological improvement at three months (defined as reduction in the NIHSS score by four or more points). There was no difference in the number of patients who were dead or dependent between those allocated intra‐arterial thrombolysis (combined OR 1.08, 95% CI 0.15 to 1.55). The addition of the recently completed <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a> trial has increased the available data four fold ‐ although the numbers are still small there is little evidence of any benefit of intra‐arterial over intravenous therapy (<a href="./references#CD000514-fig-00301" title="">Analysis 3.1</a>). </p> </section> <section id="CD000514-sec4-0013"> <h5 class="title">(b) Death</h5> <p>There were no significant differences in the number of patients who died within the first two weeks between the two groups (OR 0.96, 95% CI 0.51 to 1.79) (<a href="./references#CD000514-fig-00302" title="">Analysis 3.2</a>). Similarly, at the end of follow‐up, there was no significant difference in the number of patients who had died between the two treatment groups (OR 0.81, 95% CI 0.47 to 1.39) (<a href="./references#CD000514-fig-00303" title="">Analysis 3.3</a>). </p> </section> <section id="CD000514-sec4-0014"> <h5 class="title">(c) Symptomatic and fatal intracranial haemorrhage</h5> <p>All five studies provided data on symptomatic and fatal intracranial haemorrhage. The number of incidents is small and the confidence intervals are wide. There was no statistically significant difference between the patients allocated intra‐arterial or intravenous treatment in the number of symptomatic (OR 1.10, 95% CI 0.4 to 2.25) (<a href="./references#CD000514-fig-00304" title="">Analysis 3.4</a>) or fatal intracranial haemorrhages (OR 0.67, 95% CI 0.21 to 2.11) (<a href="./references#CD000514-fig-00305" title="">Analysis 3.5</a>). </p> </section> <section id="CD000514-sec4-0015"> <h5 class="title">(d) Major extracranial haemorrhage</h5> <p>Only two studies (<a href="./references#CD000514-bbs2-0017" title="CicconeA , BoccardiE , CoppolaC , GattiA , GuccioneA , SantilliI , et al. Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial. Proceedings of the European Stroke Conference 21‐24 May 2003, Valencia, Spain. 2003. CicconeA , ValvassoriL , PonzioM , BallabioE , GasparottiR , SessaM , et al. Intra‐arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. Journal of Neurointerventional Surgery2010;2:74‐9. ">SYNTHESIS</a>; <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>) gave details on extracranial haemorrhages describing 4/210 cases with extracranial haemorrhage in those allocated to intravenous therapy and 4/206 patients with groin haematomas two of which required surgical excision in those allocated to intra‐arterial therapy. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000514-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000514-sec1-0005"></div> <p>The data from trials comparing different doses of the same thrombolytic agent, two different agents or two routes of administration are limited to only 2527 patients. In contrast to the evidence on thrombolytic therapy versus control, where more than 9000 patients have been randomised to thrombolysis or control (<a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>; <a href="./references#CD000514-bbs2-0111" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischemic stroke. Stroke2010;41:e445‐6. ">Wardlaw 2010</a>) and more than 6000 between rt‐PA and control alone (<a href="./references#CD000514-bbs2-0112" title="WardlawJM , MurrayV , BergeE , delZoppoG , SandercockP , LindleyRL , et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta‐analysis. Lancet2012;379:2364‐72. ">Wardlaw 2012</a>), the number of included patients in the group and subgroup analysis of this companion thrombolysis review is very small. Therefore, regrettably, we are not able to report any results that will have any significant impact on everyday clinical practice. The new studies included in this update are mainly ‘dose ranging’ studies evaluating new thrombolytic agents such as desmoteplase and tenecteplase, or 'pilot' or larger interventional studies comparing intravenous thrombolysis versus intra‐arterial treatment, and therefore are very limited in their conclusions. </p> <p>Two ongoing trials are comparing intra‐arterial with intravenous thrombolysis (<a href="./references#CD000514-bbs2-0093" title="BASICS. Ongoing study To be confirmed. ">BASICS</a>; <a href="./references#CD000514-bbs2-0097" title="WangY . ITAIS. Imaging‐based thrombolysis trial in acute ischemic stroke. Internet Stroke Center. WangY , JiangW , LiaoX , DuB , ZhaoX , DongK , et al. Comparison of intravenous and intra‐arterial with tPA within 3‐6 hours guided by multi‐MRI: randomised study of 36 patients. Stroke2008;39:602. WangY , JiangW , ZhaoX , DuB , DongK , LiaoX , et al. Imaging‐based thrombolysis trial in acute ischemic stroke. http://www.abstractsonline.com/arch/RecordPrintView.aspx?LookupKey=12345&amp;RecordID=17703. 2007. ">ITAIS</a>). There is one other completed but unpublished trial (<a href="./references#CD000514-bbs2-0096" title="TrouillasP , NighoghossianN , DerexL , AdeleineP . FRALYSE, a randomised blind multicenter study comparing 0.9mg/kg for 60 minutes and 0.8mg/kg for 90 minutes in a 7 hour window. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy; 27‐28 May 2002; Lyon, France. 2002:74. ">FRALYSE</a>). The amount of data on intravenous versus intra‐arterial therapy increased four‐fold from 123 to 485 patients with the publication of <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a>. Other ongoing trials are comparing different doses of rt‐PA (e.g. <a href="./references#CD000514-bbs2-0095" title="LindleyR . ENCHANTED. Powerpoint presentation. ">ENCHANTED</a>) and should complete in the next five years. </p> <p>On the early trials of this review there was little evidence on functional outcome ‐ most of these trials did not collect such data, and two that did measure the BI (<a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>; <a href="./references#CD000514-bbs2-0011" title="MoriE , YonedaY , TabuchiM , YoshidaT , OhkawaS , OhsumiY , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology1992;42:976‐82. ">Mori 1992</a>) did it at only one month after the stroke, at which stage patients may still be improving. On a positive note, the published data in the last decade seem now to be more standardised when compared with earlier studies and typically contain basic information on baseline stroke characteristics and 90‐day mRS. Hopefully this will bear fruit in future years as larger, better conducted and reported studies become available, enabling more meaningful comparisons and meta‐analyses. </p> <p>Many of the early trials used somewhat unconventional dosing regimens, such as a once daily dose for seven days, and may have started treatment up to several days after the stroke, so it is difficult to extrapolate these results to the sort of dosing regimens used in the recent trials comparing thrombolysis with placebo (<a href="./references#CD000514-bbs2-0110" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000213.pub2] ">Wardlaw 2009</a>; <a href="./references#CD000514-bbs2-0111" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischemic stroke. Stroke2010;41:e445‐6. ">Wardlaw 2010</a>). However, most of these early trials do not provide functional outcome data, therefore data on functional outcome come from recent trials (e.g. <a href="./references#CD000514-bbs2-0009" title="DerexL , TomsickT , BrottTG , LewandowskiCA , FrankelMR , ClarkW , et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. American Journal of Neuroradiology2001;22:685‐90. Emergency Management of Stroke (EMS) Investigators. Combined intraarterial and intravenous tPA for stroke (abstract). Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA. 1996. LewandowskiCA , FrankelM , TomsickT , BroderickJ , FreyJ , ClarkW , et al. Combined intravenous and intra‐arterial r‐TPA versus intra‐arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke1999;30:2598‐605. The EMS Bridging Trial Investigators. Combined intravenous and intra‐arterial thrombolysis versus intra‐arterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovascular Diseases1996;6:184. The EMS Bridging Trial Investigators. Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke1996;27(1):2. ">EMS Bridging Trial</a>; <a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a>) testing more conventional dosing regimens. </p> <p>However, these limited data do suggest that there is some evidence that lower doses of thrombolytic agents cause fewer fatal (statistically significant) and 'clinically significant' (not statistically significant) intracranial haemorrhages. But there was no effect on the number of early deaths or total deaths at the end of follow‐up, or the death and disability outcome at the end of the follow‐up (and too few extracranial haemorrhages to make any comments). In the desmoteplase subgroup, there were significantly fewer deaths in the lower‐dose than the high‐dose subgroup. </p> <p>The data on the comparison of different thrombolytic agents (rt‐PA, t‐PA, tissue‐cultured UK, UK and tenecteplase) are extremely limited, with too few patients and outcome events to make any useful conclusions. There are no data comparing the dose of SK or of SK with other thrombolytic drugs. Desmoteplase and tenecteplase are variants of the native t‐PA with theoretically improved pharmacokinetic properties. The prematurely terminated <a href="./references#CD000514-bbs2-0019" title="HaleyEC , ThompsonJLP , GrottaJC , LydenPD , HemmenTG , BrownDL , et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke2010;41:707‐11. ">TNK‐S2B</a> trial included a subgroup (N = 31) of patients that received t‐PA; too small to draw any conclusions. <a href="./references#CD000514-bbs2-0015" title="ParsonsM . Low‐dose tenecteplase versus standard‐dose alteplase for acute ischemic stroke: an imaging‐based efficacy trial. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au2008. ParsonsM , SprattN , BivardA , CampbellB , ChungK , MiteffF , et al. A randomised trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine2012;366:1099‐107. ParsonsMW , BivardA , CampbellB , ChongKK , MiteffF , BlandinC , et al. Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial. Cerebrovascular Diseases2011;31 Suppl 2:86. ">Parsons 2012</a> had 25 patients randomised to rt‐PA and only 50 to two different doses of TNK, again rather too small for reliable conclusions. </p> <p>Recently there has been an emerging interest in the use of interventional devices to treat acute stroke (mechanical devices alone or in addition to pharmacological therapy) and many centres in developed countries worldwide offer intra‐arterial thrombolysis/thrombectomy for stroke due to large vessel occlusion (<a href="./references#CD000514-bbs2-0107" title="MazighiM , SerfatyJM , LabreucheJ , LaissyJP , MeseguerE , LavalléePC , et al. Comparison of intravenous alteplase with a combined intravenous‐endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet2010;8:802‐9. ">RECANALISE 2009</a>). This interest is often based on concepts such as that intra‐arterial therapy or mechanical devices, or both, increase recanalisation rates, or are safer because they use lower doses of thrombolytic drug (<a href="./references#CD000514-bbs2-0099" title="CicconeA , ValvassoriL , GasparottiR , ScomazzoniF , BallabioE , SterziR . Debunking 7 myths that hamper the realization of randomized controlled trials on intra‐arterial thrombolysis for acute ischemic stroke. Stroke2007;38:2191‐5. ">Ciccone 2007</a>). Until the publication of <a href="./references#CD000514-bbs2-0018" title="CicconeA . Intra‐arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP). ClinicalTrials.gov2008. CicconeA . SYNTHESIS. Local versus systemic thrombolysis for acute stroke. Personal communication2003. CicconeA , CaputoD , CasoniF , ZiniA , CheccarelliN , MusciaF , et al. SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients. Cerebrovascular Diseases2010;29 Suppl 2:121‐2. CicconeA , MottoC , SgoifoA , DaolioM , NichelattiM , ValvassoriL , et al. Synthesis expansion: an ongoing randomized controlled trial on fast track intra‐arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients. Cerebrovascular Diseases2011;31 Suppl 2:134. CicconeA , ValvassoriL , NichelattiM . SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast‐track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. International Journal of Stroke2011;6:259‐65. CicconeA , ValvassoriL , NichelattiM , SgoifoA , PonziaM , SterziR , Boccardi E for the Synthesis Expansion Investigators. Endovascular therapy for acute ischaemic stroke. New England Journal of Medicine2013;368(10):904‐13. ">SYNTHESIS EXPANSION</a> and <a href="./references#CD000514-bbs2-0041" title="BroderickJP , PaleschYY , DemchukAM , YeattsSD , KhatriP , HillMD , et al. Endovascular therapy after intravenous t‐PA versus t‐PA alone for stroke. New England Journal of Medicine2013;368(10):893‐903. BroderickJP , TomsickTA . The Interventional Management of Stroke (IMS) III Trial: an ongoing phase III trial. Proceedings of the International Stroke Conference; 24‐26 February 2010. 2010. BroderickJP , TomsickTA . The Interventional Management of Stroke (IMS) III trial: an ongoing phase III trial. International Journal of Stroke2010;5 Suppl 2:83‐4. BroderickJP , TomsickTA . The Interventional Management of Stroke (IMS) III trial: an ongoing phase III trial. Proceedings of the 20th European Stroke Conference 2011; 24‐27 May 2011; Germany, Hamburg. 2011. SohnJA , BroderickJP , SpilkerJA , TomsickTA , HillMD , JauchEC , et al. Sedation practice patterns in acute stroke endovascular therapy: The IMS III Trial experience. Stroke2011;42(3):e229‐30. TomsickTA , BroderickJP . The Interventional Management of Stroke (IMS) III Trial: an ongoing phase III trial. Proceedings of the International Stroke Conference 2011; 8‐11 February 2011;  USA, Los Angeles. 2011. ">IMS‐III</a>, the use of interventional mechanical devices was based on very limited evidence, mostly registries or case series and virtually none of it randomised (<a href="./references#CD000514-bbs2-0100" title="GalimanisA , JungS , MonoML , FischerU , FindlingO , WeckA , et al. Endovascular therapy of 623 patients with anterior circulation stroke. Stroke2012;43:1052‐7. ">Galimanis 2012</a>). IMS‐111 showed no benefit for mechanical intra‐arterial devices over intravenous rt‐PA, which taken together with the data in <a href="./references#CD000514-fig-00301" title="">Analysis 3.1</a> shows no benefit for intra‐arterial/interventional mechanical devices over intravenous rt‐PA. There is also increasing interest in the use of adjunctive methods to enhance pharmacological or spontaneous thrombolysis, for example using transcranial ultrasound (<a href="./references#CD000514-bbs2-0109" title="TsivgoulisG , EggersJ , RiboM , PerrenF , SaqqurM , RubieraM , et al. Safety and efficacy of ultrasound‐enhanced thrombolysis: a comprehensive review and meta‐analysis of randomized and nonrandomized studies. Stroke2010;41:280‐7. ">Tsivgoulis 2010</a>). At the outset of this update we were interested in evaluating the different interventional techniques and devices. However, it soon became clear that this would be premature as there are no randomised studies comparing the various interventional procedures. It was therefore more important to establish whether intra‐arterial treatment works in the first place and if it offers any particular advantage over intravenous treatment. The four randomised studies of intravenous versus intra‐arterial treatment that have been conducted so far were small (123 patients in total) and too heterogeneous to draw any definitive conclusions. Differences in stroke severity, intra‐arterial techniques, dose and technique of thrombolytic administration, use of mechanical devices, variable doses of heparin, difficulties of blinding and subsequent follow‐up assessment are only a few of the factors that may introduce significant bias in these small studies. This review indicates that intra‐arterial therapy confers no benefit over intravenous therapy either in terms of reduced dependency or death or reduced haemorrhage. At present, intravenous rt‐PA remains best practice and intra‐arterial therapy or mechanica devices should only be used in randomised trials or in exceptional situations. </p> <p>Two trials (<a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a>; <a href="./references#CD000514-bbs2-0010" title="KikuchiH , YamaguchiT , AbeH , et al. Thrombolytic therapy of SM‐9527 (duteplase; rt‐PA) in hyperacute embolic stroke ‐ the clinical efficacy and safety of thrombolytic agent in a randomized double‐blind study. Clinical Evaluation1994;22:105‐39. YamaguchiT . Randomized dose comparison (20 and 30) million international unit of (t‐PA), double blind trial in stroke. Stroke1994;25:253. YamaguchiT , KikuchiH , Hayakawa T for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double‐blind, dose‐comparison study of duteplase. In: YamaguchiT , MoriE , MinematsuK , delZoppoGJ editor(s). Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer‐Verlag, 1995. ">Kikuchi 1994</a>) contributed most of the data on significant intracranial haemorrhage, yet there were problems in the definition of the intracranial haemorrhage ‐ the authors graded the severity of the haemorrhage on the CT brain scan appearance, not on whether the haemorrhage was associated with clinical deterioration or death. <a href="./references#CD000514-bbs2-0004" title="ChenQ , HeM . Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China. Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27‐28 May, Lyon, France. 2002. ChenQ‐T . Intravenous fibrinolytic therapy for acute ischaemic stroke. In preparation2002. ">Chen 2002</a> used the term 'symptomatic intracranial haemorrhage' without an exact definition. Therefore, in some analyses we have adopted the term 'significant intracerebral haemorrhage' to take account of this. It was possible to extract the number of patients dying with mass effect (on CT brain scan), or 'massive intracranial haemorrhage' where the authors appeared to have attributed the cause of death to the haemorrhage, but nevertheless these data must be regarded with extreme caution. The patients who died of neurological causes but did not have brain imaging or autopsy may have had fatal intracranial haemorrhage, therefore the total number of deaths within the first two weeks (most likely to be of neurological causes) is a more reliable end point than fatal intracranial haemorrhage because of these definition problems. </p> <p>Thus more, larger trials are needed to answer questions on which drug, or dose of thrombolysis and if there are any situations when intra‐arterial thrombolysis with or without mechanical clot removing devices might be best, including collecting data on functional outcome as well as deaths, and intra and extracranial haemorrhages, clearly defined in terms of their clinical effect. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD000514-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000514-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/full#CD000514-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 1 Death or dependency at end of follow‐up." data-id="CD000514-fig-00101" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 1 Death or dependency at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 2 Death from all causes within about the first two weeks." data-id="CD000514-fig-00102" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 2 Death from all causes within about the first two weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 3 Total deaths from all causes at end of follow‐up." data-id="CD000514-fig-00103" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 3 Total deaths from all causes at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 4 'Significant' intracranial haemorrhage during follow‐up." data-id="CD000514-fig-00104" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 4 'Significant' intracranial haemorrhage during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 5 Fatal intracranial haemorrhage during follow‐up." data-id="CD000514-fig-00105" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 5 Fatal intracranial haemorrhage during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 6 Total major (including fatal) extracranial haemorrhage during follow‐up." data-id="CD000514-fig-00106" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Thrombolysis: higher dose versus lower dose of the same agent, Outcome 6 Total major (including fatal) extracranial haemorrhage during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Thrombolysis: one agent versus another, Outcome 1 Death or dependency at the end of follow‐up." data-id="CD000514-fig-00201" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Thrombolysis: one agent versus another, Outcome 1 Death or dependency at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Thrombolysis: one agent versus another, Outcome 2 Death from all causes within about the first two weeks." data-id="CD000514-fig-00202" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Thrombolysis: one agent versus another, Outcome 2 Death from all causes within about the first two weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Thrombolysis: one agent versus another, Outcome 3 Total deaths from all causes at end of follow‐up." data-id="CD000514-fig-00203" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Thrombolysis: one agent versus another, Outcome 3 Total deaths from all causes at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Thrombolysis: one agent versus another, Outcome 4 'Significant' intracranial haemorrhage during follow‐up." data-id="CD000514-fig-00204" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Thrombolysis: one agent versus another, Outcome 4 'Significant' intracranial haemorrhage during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Thrombolysis: one agent versus another, Outcome 5 Fatal intracranial haemorrhage during follow‐up." data-id="CD000514-fig-00205" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Thrombolysis: one agent versus another, Outcome 5 Fatal intracranial haemorrhage during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Thrombolysis: one agent versus another, Outcome 6 Total major (including fatal) extracranial haemorrhage during follow‐up." data-id="CD000514-fig-00206" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Thrombolysis: one agent versus another, Outcome 6 Total major (including fatal) extracranial haemorrhage during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 1 Death or dependency at end of follow‐up." data-id="CD000514-fig-00301" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 1 Death or dependency at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 2 Death from all causes within about the first two weeks." data-id="CD000514-fig-00302" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 2 Death from all causes within about the first two weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00303"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 3 Total deaths from all causes at end of follow‐up." data-id="CD000514-fig-00303" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 3 Total deaths from all causes at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00303">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00304"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 4 'Significant' intracranial haemorrhage during follow‐up." data-id="CD000514-fig-00304" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 4 'Significant' intracranial haemorrhage during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00304">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000514-fig-00305"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/urn:x-wiley:14651858:media:CD000514:CD000514-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_t/tCD000514-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 5 Fatal intracranial haemorrhage during follow‐up." data-id="CD000514-fig-00305" src="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Thrombolysis: different routes of administration of the same agent, Outcome 5 Fatal intracranial haemorrhage during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-fig-00305">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/media/CDSR/CD000514/image_n/nCD000514-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD000514-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Thrombolysis: higher dose versus lower dose of the same agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death or dependency at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.62, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 t‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.20, 7.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.52, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Desmoteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.49, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Tenecteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.37, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death from all causes within about the first two weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.66, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 t‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.45, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.49, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Desmoteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.47, 9.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total deaths from all causes at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.82, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 t‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.37, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.57, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Desmoteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [1.23, 8.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Tenecteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.53, 5.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 'Significant' intracranial haemorrhage during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.81, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 t‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.57, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.64, 5.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Desmoteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.17, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Tenecteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [0.38, 20.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fatal intracranial haemorrhage during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.22, 6.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 t‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.64 [1.28, 16.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.66, 8.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Desmoteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [0.33, 17.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Tenecteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.00, 6.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total major (including fatal) extracranial haemorrhage during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.93, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 t‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.88, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Desmoteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.39, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Tenecteplase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [0.15, 372.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Thrombolysis: higher dose versus lower dose of the same agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000514-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Thrombolysis: one agent versus another</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death or dependency at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.31, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tenecteplase vs t‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.31, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death from all causes within about the first two weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.38, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tissue‐cultured urokinase (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.23, 8.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 t‐PA (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.27, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total deaths from all causes at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.38, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tissue‐cultured urokinase (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.36, 9.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 t‐PA (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.26, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Tenecteplase (newer drug) vs rt‐PA (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.21, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 'Significant' intracranial haemorrhage during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tissue‐cultured urokinase (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.00, 6.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 t‐PA (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.06, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Tenecteplase (newer drug) vs rt‐PA (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.20, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fatal intracranial haemorrhage during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.12, 13.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Tissue‐cultured urokinase (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 t‐PA (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.91 [0.16, 399.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Tenecteplase (newer drug) vs rt‐PA (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.02, 9.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total major (including fatal) extracranial haemorrhage during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.15, 16.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Tissue‐cultured urokinase (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 t‐PA (newer drug) vs urokinase (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.07, 17.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Tenecteplase (newer drug) vs rt‐PA (control)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.99 [0.05, 318.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Thrombolysis: one agent versus another</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000514-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Thrombolysis: different routes of administration of the same agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death or dependency at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.75, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 rt‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.72, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.45, 9.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death from all causes within about the first two weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.51, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 rt‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.46, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.24, 7.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total deaths from all causes at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.47, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 rt‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.47, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 'Significant' intracranial haemorrhage during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.54, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 rt‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.61, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fatal intracranial haemorrhage during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.21, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 rt‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.27, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Urokinase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 1.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Thrombolysis: different routes of administration of the same agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000514.pub3/references#CD000514-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000514.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000514-note-1210">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD000514-note-1208">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD000514-note-1207">한국어</a> </li> <li class="section-language"> <a class="" href="pt#CD000514-note-1206">Português</a> </li> <li class="section-language"> <a class="" href="ta#CD000514-note-1209">தமிழ்</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000514\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000514\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000514\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000514\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000514\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000514.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000514.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000514.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000514.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000514.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715930112"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000514.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715930116"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000514.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d931dbe109368',t:'MTc0MDcxNTkzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 